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ABSTRACT 
Catharanthus roseus extract is traditionally used to treat different diseases including 
cancer in Southeast Asia. Acanthus ilicifolius, is a mangrove medicinal plant, and is 
widely used by the local inhabitants of the Sundarbans (India) to treat a variety of 
diseases. The aim of current research is to assess the chemoprotective outcomes of 
ethanolic extracts of C. roseus and A. ilicifolius against azoxymethane (AOM) induced 
colonic aberrant crypt foci (ACF) in rats. The bioactivities of the crude ethanol extracts 
of C. roseus and A. ilicifolius were investigated in both of their in vitro antioxidant and 
in vivo oral toxicity tests. Antioxidant activity was evaluated by different assays, 
including: 2, 2-diphenlyl-1-picrylhydrazyl (DPPH), ferric reducing antioxidant power 
(FRAP), total phenolic content (TPC) and total flavonoids content (TFC) assays. Five 
groups of rats, normal control group were given subcutaneous injection of normal 
saline, once weekly for 2 weeks. The AOM control group, reference group and 
treatment groups were given subcutaneous injection of AOM, 15 mg/kg body weight, 
once weekly for 2 weeks each. Normal and AOM control groups continued on 10% 
Tween 20 feeding for 8 weeks. Reference group continued on 35 mg/kg of 5-
Fluorouracil intraperitoneal injection once weekly for 8 weeks, and treatment groups 
continued on 250 and 500 mg/kg C. roseus and A. ilicifolius extracts feeding for 8 
weeks respectively. After 60 days treatment, all rats were sacrificed. Colons were 
evaluated grossly, histopathology and immunohistochemistry staining for ACF. Also 
body weight, biochemical parameters, catalase (CAT), superoxide dismutase (SOD) 
activities and lipid peroxidation (MDA) level in the colon homogenates were tested. 
Gene expressions also were studied for p53, Bax and Bcl2 by real time PCR. In 
addition, the crude extracts of C. roseus and A. ilicifolius and their isolated fractions 
were investigated against HT29 and (CCD841) human cell line cell line, and the 
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percentage of inhibition by using MTT assay was assessed. Our results revealed that, 
extracts of C. roseus and A. ilicifolius exhibited high free radical scavenging activity at 
the same time, showed high total phenolic and flavonoids contents. Acute toxicity test 
could not demonstrate any morbidity as well as mortality. Rats treated with C. roseus 
and A. ilicifolius showed significantly decreased total colonic ACF formation by 61 % 
to 65 % and 53 % to 65 % respectively when compared with AOM control group and 
they were effectively comparable to that of 5-Fluorouracil, a standard cemoprotective 
agent. Histopathological study confirmed the result. In immunohistochemical staining, 
proliferating nuclear cell antigen (PCNA) positive cells were significantly higher in 
AOM control group than C. roseus and A. ilicifolius-treated groups. C .roseus showed 
significant increase in total protein, albumin, hemoglobin, white blood cell, SOD and 
CAT, and significant decrease in MDA, LDH and urea when contrasted with AOM 
control group. While A. ilicifolius showed significant increase in total protein, albumin, 
Hb, SOD and CAT, and significant decreased in MDA and urea when compared with 
AOM control group. RT-PCR showed that C. roseus and A. ilicifolius caused change in 
regulation of gene expression of p53, anti-apoptotic protein Bcl-2 and pro-apoptotic 
protein Bax and inverting the Bcl-2/Bax ratio to <1. Moreover, the results observed 
from the MTT assay showed that C. roseus and A. ilicifolius plants extract stimulated 
the normal cell line (CCD841) proliferation in vitro in a dose-dependent manner, at the 
same time both extracts have remarkable activity against cancer cell line (HT29). The 
active constituents of the fractions that are proved to have chemoprotective activity in 
C. roseus are vindoline, vindolidine and ajmalicine while in A. ilicifolius is stigmasterol. 
The results of the current study showed that C. roseus and A. ilicifolius may be an 
effective herbal and efficient remedial for chemical-induced against cancer in rats colon.  
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ABSTRAK 
Catharanthus roseus digunakan secara tradisional untuk merawat penyakit yang berbeza 
termasuk kanser di Asia Tenggara. Acanthus ilicifolius, adalah tumbuhan perubatan bakau, 
dan digunakan secara meluas oleh penduduk tempatan Sundarbans (India) untuk merawat 
pelbagai penyakit. Tujuan kajian semasa adalah untuk menilai hasil chemoprotective 
ekstrak ethanolic C. roseus dan A. ilicifolius terhadap azoxymethane (AOM) disebabkan 
kolon menyeleweng kubur tumpuan (ACF) pada tikus. The bioactivities daripada ekstrak 
etanol mentah C. roseus dan A. ilicifolius disiasat dalam kedua-dua mereka antioksida in 
vitro dan dalam ujian Ketoksikan oral vivo. Aktiviti antioksida yang telah dinilai oleh ujian 
yang berbeza, termasuk: 2, 2-diphenlyl-1-picrylhydrazyl (DPPH), kuasa penurunan ferik 
(FRAP), jumlah kandungan fenolik (TPC) dan flavonoid jumlah kandungan (TFC) ujian. 
Lima kumpulan tikus, kumpulan kawalan normal diberikan suntikan subkutaneus masin 
biasa, sekali seminggu selama 2 minggu. Kumpulan kawalan AOM, kumpulan rujukan dan 
kumpulan rawatan telah diberikan suntikan subkutaneus AOM, 15 mg / kg berat badan, 
sekali seminggu selama 2 minggu setiap. Kumpulan kawalan normal dan AOM berterusan 
10% Tween 20 makan selama 8 minggu. Kumpulan rujukan berterusan 35 mg / kg 5-
Fluorouracil suntikan intraperitoneal sekali seminggu selama 8 minggu, dan kumpulan 
rawatan diteruskan pada 250 dan 500 mg / kg C. roseus dan A. ilicifolius ekstrak makan 
untuk 8 minggu masing-masing. Selepas rawatan 60 hari, semua tikus telah dikorbankan. 
Titik bertindih dinilai terlalu, histopatologi dan mengotorkan Immunohistokimia untuk 
ACF. Juga berat badan, parameter biokimia, katalase (CAT), superoksida dismutase (SOD) 
aktiviti dan lipid peroksidaan peringkat (MDA) dalam homogenates kolon telah diuji. 
Ungkapan gen juga dikaji untuk p53, Bax dan Bcl2 oleh masa PCR sebenar. Di samping 
itu, ekstrak mentah C. roseus dan A. ilicifolius dan pecahan terpencil mereka telah disiasat 
terhadap HT29 dan (CCD841) sel manusia garis sel talian, dan peratusan perencatan dengan 
menggunakan MTT assay telah dinilai. Keputusan kami menunjukkan bahawa, ekstrak C. 
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roseus dan A. ilicifolius dipamerkan aktiviti percuma yang tinggi memerangkap radikal 
pada masa yang sama, menunjukkan jumlah fenolik yang tinggi dan flavonoid kandungan. 
Ujian ketoksikan akut tidak boleh menunjukkan mana-mana morbiditi serta kematian. 
Tikus yang dirawat dengan C. roseus dan A. ilicifolius menunjukkan ketara menurun 
jumlah pembentukan ACF kolon sebanyak 61% kepada 65% dan 53% kepada 65% 
masing-masing berbanding dengan kumpulan kawalan AOM dan mereka berkesan 
setanding dengan 5 Fluorouracil, standard ejen cemoprotective. Kajian histopatologi 
mengesahkan keputusan. Dalam mengotorkan immunohistochemical, membiak antigen sel 
nuklear (PCNA) sel-sel yang positif adalah lebih tinggi dalam kumpulan kawalan AOM 
daripada C. roseus dan A. ilicifolius dirawat. C. roseus menunjukkan peningkatan ketara 
dalam jumlah protein, albumin, hemoglobin, sel darah putih, SOD dan CAT, dan 
penurunan ketara dalam MDA, LDH dan urea apabila dibandingkan dengan kumpulan 
kawalan AOM. Walaupun A. ilicifolius menunjukkan peningkatan ketara dalam jumlah 
protein, albumin, Hb, SOD dan CAT, dan ketara menurun dalam MDA dan urea 
berbanding dengan kumpulan kawalan AOM. RT-PCR menunjukkan bahawa C. roseus 
dan A. ilicifolius disebabkan perubahan dalam peraturan gen p53, anti-apoptotic protein 
Bcl-2 dan pro-apoptotic protein Bax dan menyongsang nisbah Bcl-2/Bax hingga <1. Selain 
itu, keputusan dilihat dari assay MTT menunjukkan bahawa C. roseus dan A. tumbuhan 
ilicifolius ekstrak dirangsang garis sel normal (CCD481) percambahan in vitro dengan cara 
yang bergantung kepada dos, pada masa yang sama kedua-dua ekstrak mempunyai aktiviti 
luar biasa terhadap sel kanser line (HT29). Juzuk aktif pecahan yang terbukti mempunyai 
aktiviti chemoprotective di C. roseus adalah vindoline, vindolidine dan ajmalicine 
manakala di A. ilicifolius adalah stigmasterol. Keputusan kajian semasa menunjukkan 
bahawa C. roseus dan A. ilicifolius mungkin merupakan pemulihan yang berkesan herba 
dan berkesan untuk bahan kimia disebabkan daripada kanser pada tikus kolon. 
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INTRODUCTION 
1.1. Introduction 
     Colorectal cancer (CRC) is one of the most prevalent causes of cancer deaths in 
developed countries, including the United States (Hisamuddin & Yang, 2006). The 
etiology of colon cancer is multifactorial including familial, environmental and dietary 
agents. Despite several advancements in the understanding of the processes involved in 
carcinogenesis the currently available therapies that include surgery, radiation and 
chemotherapeutic drugs still only have limited success for treating the advanced stages 
of colon cancer (Boursi & Arber, 2007). 
      To that end nutritional intervention is an effective and promising complimentary 
strategy for controlling the incidence of colon cancer (Hoensch & Kirch, 2005). Several 
epidemiological and experimental studies have indicated that plant products exert a 
protective influence against this disease, and beneficial effects may be partly 
attributable to polyphenolic phytochemicals, which have a wide range of 
pharmacological properties (Higdon et al., 2007). Moreover, the search for putative 
chemopreventive compounds with minimal toxicity raises particular interest in regards 
to phytochemicals. Colorectal carcinogenesis provides a huge screen including years 
approaches (Boursi & Arber, 2007). With the aid of efficient preclinical designs it is 
possible to assess the effect of potential chemopreventive agents on the carcinogenic 
process. These preclinical designs consist of the induction of colon carcinogenesis in 
rats by the administration of the chemical carcinogen azoxymethane (AOM) (Bird & 
Good, 2000).  
     AOM and its precursor compound dimethylhydrazine are alkylating agents that 
cause DNA mutation by binding methyl or alkyl groups to guanine residues, resulting in 
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G to A transition mutations (Dipple, 1995). Aberrant crypt foci (ACF) are putative pre-
neoplastic lesions in the colons of both animals and humans (Cheng & Lai, 2003). They 
serve as intermediate biomarkers to rapidly evaluate the chemopreventive potential of 
several agents, including naturally occurring agents against colon cancer (Corpet & 
Taché, 2002). Aberrant crypt foci (ACF) are hyper proliferative lesions located in the 
human colon as well as carcinogen-treated laboratory creatures that share ordinary 
characteristics with colon tumours (Bird, 1995). In addition ACF are recognized as 
colonic carcinogenesis biomarkers as well as alleged precursors of colon cancers 
(Takayama et al., 1998).  
     ACFs are monoclonal gatherings of strange crypts always formed in a dose-
dependent way in reaction to carcinogen exposure (Bird, 1987). Within 6–8 hours of 
post exposure to AOM, crypt progenitor cells undergo apoptosis in response to DNA 
damage. Progenitor cells that avoid apoptosis then start a proliferative response 48–72 
hours afterwards (Hirose et al., 1996). These foci of aberrant crypts started as  
monoclonal (Ponder & Wilkinson, 1986) and  arise by a process of incomplete crypt 
fissioning (Siu et al., 1999).  
           Catharanthus roseus (L) G. Don. (Family: Apocynaceae) is a plant whose leaves 
have been traditionally used for the treatment of cancer, Hodgkin’s disease, leukemia, 
rhrumatism, enorrhagia, indigestion, dyspepsia, dysmenorrheal, hypertension, diabetes, 
menstrual disorders, malaria and skin diseases (Holdsworth, 1990; Natarajan et al., 
2012). This plant has several therapeutic properties including wound healing (Nayak & 
Pinto Pereira, 2006), anticancer (Lu et al., 2003), antihyperglycemic (Rasineni et al., 
2010a), antibacterial (Ramya, 2008) along with biochemical specialization (Murata et 
al., 2008) such as enhancing the kidney and liver functions (Adekomi, 2010). C. roseus 
has a variety of medicinal properties, such as leukaemia treatment, the cure of Hodgkin 
infection (Jaleel et al., 2007), hypoglycaemia (Kar et al., 2003), wound healing (Nayak 
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& Pereira, 2006), significant reduction of protein levels, lipid peroxidation of liver 
(Iweala & Okeke, 2005), hypolipidaemic properties (Rasineni et al., 2010b), antioxidant 
activity (Rasool et al., 2011) and antibacterial efficacy (Raza et al., 2009). 
Phytochemically, C. roseus contains serpentine, vindoline, catharanthine, tabersonine, 
vincristine, vinblastine, ajmalicine, tryptamine, tryptophan and secologanine 
(Tikhomiroff & Jolicoeur, 2002). 
            Acanthus ilicifolius Linn (Family: Acanthaceae) is a spiny herb of the mangrove 
species, distributed widely throughout Southeast Asia where it is used locally for the 
treatment of cancers, kidney stones, snakebites, rheumatism, paralysis, ulcers, wound 
healing and asthma (Wöstmann & Liebezeit, 2008a). The leaves of A. ilicifolius has 
been reported to exhibit hepatoprotective (Babu et al., 2001) and tumour reducing 
activities (Babu et al., 2002). Furthermore antioxidant, hepatoprotective, leishmanicidal, 
tumour reducing and anticancer activities of various extracts of A. ilicifolius have been 
reported (Babu et al., 2001, 2002). Plant derived compounds such as flavonoids (Osawa 
et al., 1990), terpenes and alkaloids (Di Carlo et al., 1999) have pharmacological 
properties including cancer chemopreventive effects and cytotoxicity (Roja & Heble, 
1994). The phytochemical literature reveals the presence of 2-benzoxazolinone, 
lignanglucosides, benzoxazinoideglucosides, flavone glycosides and phenylethanoid 
glycosides (Kanchanapoom et al., 2001a; Wu et al., 2003). To date, there are no studies 
with in vivo (colon) cancer models in evaluating anti-carcinogenic potential of A. 
ilicifolius. Thus, our investigation in well-established models of chemically-induced 
colon carcinogenesis helped to validate the chemopreventive effects of A. ilicifolius in 
AOM-induced aberrant crypt foci in rat colons as a form of animal modeling. 
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1.2 Objectives of the study 
1.2.1 General objective 
The main objective of this study is to evaluate the chemoprotective effects of C. roseus 
and A. ilicifolius against AOM-induced aberrant crypts foci in rats, using rats as an 
experimental model animal. The understanding of these affects should pave the way to 
providing an alternative therapy for treating colorectal cancer. 
1.2.2 Research objectives 
1. To determine the antioxidant properties of C. roseus and A. ilicifolius extracts in 
vitro and in vivo. 
2. To determine the acute toxicity of the use of C. roseus and A. ilicifolius crude 
leaf extracts in rats. 
3. To assess the preventative effects of C. roseus and A. ilicifolius extracts in 
AOM-induced ACF in rats. 
4. To investigate the possible mechanism of action for the preventative effect of C. 
roseus and A. ilicifolius extracts on AOM-induced aberrant crypt foci in rats. 
5. To determine the cytotoxicity of crude extracts and fractions isolated from C. 
roseus and A. ilicifolius extracts by MTT assay. 
6. To identify the active constituents of the C. roseus and A. ilicifolius extracts by 
HPLC and LC-MS. 
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LITERATURE REVIEW 
2.1 Colorectal cancer 
Colorectal cancer is the most common gastrointestinal cancer and a major cause of 
cancer deaths worldwide. It also called large bowel cancer or colon cancer and includes 
cancerous growths in the colon, appendix and rectum. colorectal cancer is the fourth 
leading causes of cancer deaths worldwide (Yusoff et al., 2012). The incidents of 
colorectal cancer is rising in many countries (Béjar et al., 2012), especially in the Asian 
region (Sung et al., 2005). Around 60% of cases are currently diagnosed in the 
developed world. In 2008, it is approximated that 1.23 million new cases of colorectal 
cancer globally were clinically diagnosed, and that it killed 608,000 people (Ferlay et 
al., 2010). In Malaysia, colorectal cancer is the most common cancer in males and the 
third most common in females, with the majority of patients being above 50 years old. It 
also contributes to the highest number of hospital discharges due to neoplasm related 
problems (Yusoff et al., 2012).  
 Early diagnosis can reduce mortality due to colorectal cancer and the incidence 
of malignant neoplasm. Screening through faecal occult blood test (FOBT), 
sigmoidoscopy and colonoscopy is proven to reduce mortality (Walsh & Terdiman, 
2003). Therefore, many countries have produced guidelines to include screening for 
colorectal cancer and included colorectal cancer screening in their national screening 
programmes (Power et al., 2009). Despite that, screening activity is still low in many 
countries, including the developed world. In the Asian region, The Asia Pacific 
Consensus recommends screening for colorectal cancer from the age of 50 years 
onwards (Sung et al., 2008). In Malaysia, guidelines on screening for colorectal cancer 
were introduced in 2001 (Yusoff et al., 2012), recommending annual screening to 
individuals at average risk using FOBT. However, information on cancer screening 
participation in Malaysia is lacking, except for cervical cancer screening and breast 
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cancer screening. Even then, the uptake of Pap smear screening is only 26% and 
mammography uptake is only 3.8% (Lim, 2002). Considering that cervical cancer 
screening is more established than colorectal cancer screening, it is expected that the 
uptake of colorectal cancer screening would be lower. This is probably the reason why 
the majority of colorectal cancer patients in Malaysia present themselves in an advanced 
stage of the illness (Goh et al., 2005). 
2.1.1 Signs and symptoms of colorectal cancer 
Colorectal cancer symptoms and signs depend on the location of tumours in the bowel, 
and whether it has extended to elsewhere in the body (metastasis). The stellate notice 
signs include: blood in the stool, worsening constipation, fever, loss of appetite, nausea, 
weight loss and vomiting in someone over 50 years of age. While anaemia or rectal 
bleeding are high-risk features in those over the age of 50 (Astin et al., 2011), other 
usually substantive symptoms including weight loss and change in bowel habits are 
typically only around if associated with bleeding. Cancers that are pent within the wall 
of the colon are predominantly curable with surgery, while cancer that has distributed 
vastly around the body is predominantly not curable via surgery, therefore the focus 
moves on to extending the person's life via chemotherapy and other treatments designed 
to generally improve the patients quality of life (Adelstein et al., 2011; Astin et al., 
2011). 
2.1.2 Cause of colorectal cancer 
Colorectal cancer mostly occurs due to increasing age and lifestyle choices, with only a 
minority of cases related with implied genetic disorders. It typically begins in the lining 
of the bowel and if untreated, can grow into the muscle layers, and then through the 
bowel wall. Screening is successful at decreasing the chance of dying from colorectal 
cancer and is recommended beginning at the age of 50 and continuing until a person is 
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75 years old. Diagnosis of bowel cancer is usually by sigmoidoscopy or colonoscopy. 
Little or no genetic risk of colon cancer occurs in more than 75-95% of people (Watson 
& Collins, 2011). Other risk factors include male gender, older age, alcohol, high intake 
of fat or red meat, smoking and obesity, a lack of physical exercise (Watson & Collins, 
2011).  
2.1.3 Inflammatory bowel disease 
In cases of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis 
there is an increased risk of contracting colon cancer (Jawad et al., 2011). Prevention 
with aspirin and regular colonoscopies are recommended for these high risk groups (Xie 
& Itzkowitz, 2008).  However, people with inflammatory bowel disease account for less 
than 2% of colon cancer cases per year. In those with Crohn's disease 2% get colorectal 
cancer after 10 years, 8% after 20 years, and 18% after 30 years. In those with 
ulcerative colitis around 16% develop either a cancer precursor or cancer of the colon 
over 30 years (Triantafillidis et al., 2009).
  
2.1.4 Types and molecular genetics 
Genetic analysis shows that rectal and colon tumours are basically genetically the same 
cancer (Muzny et al., 2012). Those with a family history in two or more first-degree 
relatives have a two to three fold increased risk of disease, and this group accounts for 
about 20% of all cases. Several genetic syndromes are also related with higher rates of 
colorectal cancer.  
     Lynch syndrome or (HNPCC) is the most common type of hereditary nonpolyposis 
colorectal cancer and is present in about 3% of people with colorectal cancer. Other 
syndromes that are strongly associated include: familial adenomatous polyposis (FAP) 
and Gardner syndrome, in which cancer nearly always occurs and is the cause of 1% of 
cases (Half et al., 2009). Genetics, epidemiological data, and experimental, suggest that 
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colorectal cancer develops from complex interactions between environmental factors 
and inherited susceptibility. The existing hypothesis is that adenomatous polyps are the 
precursors of the great majority of colorectal cancers. Thus a gauge that can detect and 
reduce the prevalence of these adenomatous polyps can reduce the risk of colorectal 
cancer. Amongst colorectal cancer, some are considered to be invasive cancers that are 
confined within the wall of the colon (TNM stages I and II), these are curable with 
surgery. If untreated, they extend to regional lymph nodes (stage III), where up to 73% 
are curable by surgery and chemotherapy. Cancer that metastasizes to distant sites 
(stage IV) is ordinarily not curable, although chemotherapy can prolong survival, and in 
rare cases, surgery and chemotherapy combined have seen patients through to a cure.  
     Hereditary and environmental factors play a role in CRC development. For example, 
sporadic cancer. Those cases that occur in individuals over 50 without any identifiable 
predisposing factors, account for greater than 75% of the various causes of CRC, while 
the remaining are accounted for by inflammatory bowel diseases and familial incidence. 
      Familial adenomatous polyposis (FAP) is an autosomal dominant colon cancer 
syndrome that appears upon the inheritance of a single copy of a mutant gene (Farinella 
et al., 2010; Kucherlapatia et al., 2001).  FAP syndrome is described by the appearance 
of hundreds to thousands of colonic polyps during the second and the third decade of 
life and is assumed to be the least common type of colon cancer (Farinella et al., 2010; 
Kucherlapatia et al., 2001). The gene responsible for FAP was recognized in (1991) by 
Groden and termed the adenomatous polyposis coli (APC) gene. The APC gene was 
recognized on chromosome 5q as one of the genes generally deleted in some FAP 
kindred’s (Groden et al., 1991; Kinzler et al., 1991). It encodes a huge protein (about 
2850 amino acids) that forms a complex with axin and helps glycogen synthase 
kinase3β to phosphorylate N-terminal serine/threonine residues of β-catenin, 
accelerating its rapid degradation through ubiquitylation (Polakis, 1999).  
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      Hereditary non-polyposis colon cancer (HNPCC), also known as lynch syndrome, is 
another autosomal dominant disorder that represents 2-4% of colon cancer cases 
(Jasperson et al., 2010; Kucherlapatia et al., 2001).  Individuals with HNPCC are also at 
increased risk of other cancers, such as kidney, stomach, biliary, small bowel and 
ovarian (Jasperson et al., 2010). The mutations in any mismatched repair genes mut l 
homolog 1 [MLH1], mut s homolog 2 [MSH2], mut s homolog 6 [MSH6], postmeiotic 
segregation increased 1 [PMS1], post-meiotic segregation increased 2 [PMS2], and mut 
s homolog 3 [MSH3] results in HNPCC (Neibergs et al., 2002). Mutations in MLH1 
and MSH2 are usually observed mutations in HNPCC patients (Markowitz & 
Bertagnolli, 2009). 
2.1.5 Pathogenesis of colorectal cancer 
Colorectal cancer is a disease originating from the epithelial cells lining the colon or 
rectum of the gastrointestinal tract, most consistently as a result of mutations in 
the WNT signaling pathway that artificially increase signaling activity. The mutations 
can be inherited or acquired, and most probably occur in the intestinal crypt stem cell. 
  On the molecular and cellular level, colorectal cancer begins with a mutation to 
the WNT signaling pathway, when WNT binds to a receptor on the cell that sets in 
motion a chain of molecular proceedings that ends with β-catenin moving into the 
nucleus and activating a gene on DNA. In colorectal cancer, genes along this chain are 
damaged, usually by a gene called APC, which is a "brake" that works on the WNT 
pathway. Without a working APC brake, the WNT pathway is stuck in the "on" position 
(Markowitz & Bertagnolli, 2009). If the APC gene is mutated, glycogen synthase 
kinase3β cannot phosphorylate β-catenin and therefore stabilized β-catenin accumulates 
in the cytoplasm and moves to the nucleus, where it activates TCF/LEF transcription 
factors to transcribe WNT target genes (Korinek et al., 1997). Activation of the 
canonical WNT pathway in the colonic epithelium seems to be one of the key events in 
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the polyp initiation process, as shown in Figure 2.1 (Oshima et al., 1997; Taketo, 2006). 
While APC is mutated in most colon cancers, some cancers have increased β-catenin 
because of mutations in β-catenin (CTNNB1) that block its degradation, or they have 
mutations in other genes whose functions are analogous to APC such as AXIN1, 
AXIN2, Transcription factor 7-like 2 (TCF7L2), or Naked cuticle 1(NKD1) (Markowitz 
& Bertagnolli, 2009).           
      Beyond the defects in the WNT-APC-beta-catenin signalling pathway, other 
mutations must occur for the cell to become cancerous. The p53 protein, produced by 
the TP53 gene, normally monitors cell division and kills cells if they have WNT 
pathway defects. Eventually, a cell line acquires a mutation in the tumour protein 
(TP53) gene and transforms the tissue from an adenoma into an invasive carcinoma 
(sometimes the gene encoding p53 is not mutated, but another protective protein named 
BAX is mutated).  
     Other apoptotic proteins commonly deactivated in colorectal cancers are TGF-β and 
DCC (Deleted in colorectal Cancer). TGF-β has a deactivating mutation in at least half 
of colorectal cancers. Sometimes TGF-β is not deactivated, but a downstream protein 
named SMAD is. DCC commonly has deletion of its chromosome segment in colorectal 
cancer (Mehlen & Fearon, 2004).  
     Some genes are oncogenes they are over expressed in colorectal cancer. For 
example, genes encoding the proteins KRAS, RAF, and PI3K, which normally stimulate 
the cell to divide in response to growth factors, can acquire mutations that result in 
over-activation of cell proliferation. The chronological order of mutations is sometimes 
important, with a primary KRAS mutation generally leading to a self-limiting 
hyperplastic or borderline lesion, but if occurring after a previous APC mutation it often 
progresses to cancer (Vogelstein & Kinzler, 2004). PTEN, a tumour suppressor, 
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normally inhibits PI3K, but can sometimes become mutated and deactivated 
(Markowitz & Bertagnolli, 2009). Comprehensive genome-scale analysis have revealed 
that colorectal carcinomas are clearly separable into hypermutated and non-
hypermutated tumour types. In addition to the oncogenic and inactivating mutations 
described for the genes above, non-hypermutated samples also contain mutated 
CTNNB1, FAM123B, SOX9 and ARID1A. Progressing through a distinct set of genetic 
events, hypermutated tumours display mutated forms of ACVR2A,TGFBR2, MSH3, 
MSH6, SLC9A9, TCF7L2, and BRAF. The common theme among these genes, across 
both tumour types, is their involvement in WNT and TGF-β signalling pathways, which 
in turn results in increased activity of MYC, a central player in colorectal cancer 
(Muzny et al., 2012). 
 
 
Figure 2.1: Wnt signalling activation in colon cancer cells (Taketo, 2006). 
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2.1.6 Pathology of colorectal cancer 
The classifications of colon cancers are well-differentiated, moderately well 
differentiated, or poorly differentiated on the degree of preservation of normal glandular 
architecture and cytologic features. Gradually more poor differentiation is perhaps a 
histological marker of further underlying genetic mutations, but the mutations 
associated with poor differentiation are currently unknown. About 20% of cancers are 
poorly differentiated. They have a poor prognosis. About 15% of colon cancers are 
classified as mucinous or colloid, because of prominent intracellular accumulation of 
mucin. These cancers are more aggressive (Kanazawa et al., 2002). About 65% of colon 
cancers are distal to the splenic flexure and potentially detectable by sigmoidoscopy 
(McCallion et al., 2001). Contrariwise, about 35% of colon cancers are proximal to the 
sigmoid and not detectable by flexible sigmoidoscopy. Colon cancer can occur in a 
pedunculated polyp, sessile polyp, mass or stricture. Small polyps rarely contain cancer. 
Only about 1% of diminutive polyps contain cancer. Cancer in a sessile polyp may 
metastasize faster than cancer in a pedunculated polyp because of the closer proximity 
of the lymphatic drainage (Nivatvongs, 2002). 
2.1.7 Aberrant crypt foci (ACF) 
Aberrant crypt foci were first disclosed by Bird in (1987). Treating mice with the 
carcinogen azoxymethane (AOM) induced the growth of colonic crypts that were larger, 
darker staining and thicker than normal crypts when conceived with methylene blue. 
Aberrant crypts were first noticed in the surrounding normal colonic mucosa of patients 
with colon cancer. In human mucosa, the crypt clusters found appear raised from the 
normal mucosal surface of the colon (Pretlow et al., 1991). Bird (1995) reported the role 
of aberrant crypt foci in knowing the pathogenesis of colon cancer. The Case for 
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Modulation as a Biomarker for Colon Cancer (Takayama, (2005) elucidate the 
detection, gene abnormalities and clinical usefulness of ACF. 
 Wargovich (2010) mentioned the use of ACF as a biomarker in their research 
Aberrant Crypt Foci: Due to the observed rapid conversion of intestinal and colonic 
cells under normal conditions, it is expected that aberrant crypts would replicate at the 
same rate, if not faster than normal crypts. However, in humans there is discordant 
evidence as to how much of an increase in replication exists, if any (Wargovich et al., 
2010). 
 This discrepancy can be due to many factors, most notably differences between 
the methods of analysis and sampling in various studies defining colonic epithelial cell 
proliferation (Jass et al., 2003). Aberrant crypt replication is basically identical to that 
of normal crypts, with the replication process beginning at the bottom of the crypt 
pushing cells upward and outwards to form new colonic crypts, in addition to 
replenishing the cells in the original crypt. This is a budding and branching process, 
known as crypt fission, which forms larger sized foci over time (Fujimitsu et al., 1996). 
This process occurs at an increased rate in various diseased states of the bowel (Figure 
2.2). 
 
Figure 2.2: Stages of ACF formation in colon cancer (Corpet & Taché, 2002) 
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As mentioned, ACF was first noticed in the colon epithelium of rodents treated with 
chemical carcinogens. They are single to multiple crypt clusters of abnormally staining 
crypts after short-term staining with either indigo-carmine solutions or methylene-blue 
and fixation with either alcohol-based fixatives or buffered formalin (Bird, 1987).  
 ACF are readily visible ordinarily with the assistance of a dissection microscope 
at a magnification at 40x strength. There are many examples in literature describing the 
key histopathological signatures of ACF, though categorizing them in humans has met 
with considerable controversy (Gupta et al., 2009; Gupta et al., 2007; Khare et al., 
2009; Lance & Hamilton, 2008). Microscopically, a discrepancy has been made 
between dysplastic ACF and non-dysplastic ACF (often including serrated hyperplastic 
ACF) (Wargovich et al., 2010). Before 1990, the gold standard endpoint for 
chemoprevention in rodents was the incidence of macroscopic tumours and colon 
cancers; colon adenomas and adenocarcinomas induced by a chemical carcinogen. 
 Though these endpoints are clearly related to cancer, the have three major 
drawbacks: (i) a tumour requires a long time to develop (usually 5-8 months); (ii) each 
tumour must be confirmed by histology, which is long and costly; (iii) each animal 
brings little information to the study (each rat has either no tumour or a tumour), thus 
large groups of rats are needed for statistical analysis (typically 30 rats or more per 
group). In lieu of the above draw backs, ACF was found to be advantageous as endpoint 
chemoprotective screening biomarkers because (i) ACF was induced by all colon 
carcinogens in a dose and species dependant manner; (ii) their number and growth were 
modified by the modulators of colon carcinogenesis, and they predicted the tumour 
outcome in several rodent studies; (iii) they correlate with colon cancer risk, and 
adenoma size and number in humans; (iv) the morphological and genotypic features of 
ACF in human colons were similar to those in animal colons, and many alterations are 
 17 
 
similar in ACF and in tumours; (v) some ACF show dysplasia, and carcinoma were 
observed in rodents and humans‟ ACF (Corpet & Taché, 2002). 
 This is why ACF is now widely used as a preliminary endpoint in colon cancer 
chemoprevention studies, as it provides a simple and economical tool for preliminary 
screening of potential chemopreventive agents, and it allows a quantitative assessment 
of the mechanisms of colon carcinogenesis. 
2.2 Azoxymethane AOM 
Azoxymethane (methyl-methylimino-oxidoazanium) is an oxide compound of 
azomethane, with the molecular formula of C2H6N2O, whose chemical structure is 
shown in (Figure 2.3). It is a carcinogenic and neurotoxic chemical, with wide 
applications in biological research, such as being particularly effective in inducing colon 
carcinomas. Besides been soluble in water, this compound is reported to be sensitive to 
prolonged exposure to air and elevated temperatures.  
 
Figure 2.3: Chemical structure of Azoxymethane (methyl-methylimino-oxidoazanium) 
The use of azoxymethane to induce foci of aberrant crypts in rats has been reported in 
many papers (Adler, 2005; Velmurugan et al., 2008; Wargovich et al., 2010) studied the 
Chemoprevention effect of zerunbone isolated from Zingiber zerumbet by using 
azoxymethane to induce aberrant crypt foci in male F344 rats. The researchers induced 
ACF in these rats by subcutaneous injections of AOM (15mg/kg body weight) for two 
weeks. They assessed the effects of zerumbone on cell proliferation activity by counting 
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silver-stained nucleolar organizer regions protein (AgNORs) in colonic cryptal cell 
nuclei. 
     Challa (1997) reported the induction of aberrant crypt foci using azoxymethane 
while studying the effect of phytic acid and green tea in interactive suppression of ACF. 
Magnuson (2000) published an extensive study on the increased susceptibility of adult 
rats to AOM-induced aberrant crypt foci. Verghese (2002) studied the suppression of 
AOM-induced ACF using dietary insulin. 
     In general, azoxymethane is commonly used as a model for colon cancer induction. 
It can induce colon cancer similar to the pathogenesis of human sporadic colon cancer. 
Thus, it has been widely used in the study of the molecular biology, prevention and 
treatment of colon cancer. After administration, AOM is metabolised into 
methylazoxymethanol by CYP2E1, which causes DNA mutations. Mutation of K-ras 
activates this pathway and its downstream PI3K/Akt pathway and Mitogen-activated 
protein kinase (MAPK) pathway. Mutation of β-catenin also prevents it from being 
degraded by GSK-3 and an accumulation of β-catenin leads to cell proliferation. TGFβ, 
a pro-apoptotic protein, is thus inhibited. These changes form the basis of AOM 
carcinogenesis (Chen & Huang, 2009). 
2.2.1 Metabolism for AOM causing colon cancer 
Azoxymethane does not react with DNA directly, it has to be activated in vivo to 
develop carcinogenesis. Azoxymethane is metabolised by cytochrome P450, 
specifically isoform CYP2E1. The first step is the hydroxylation of the methyl group of 
AOM to form methylazoxymethanol (MAM). Methylazoxymethanol then breaks down 
into formaldehyde and a highly reactive alkylating species, probably the 
methyldiazonium. This chemical actually causes alkylation of DNA guanine to O6-
MEG and to O4-methylthymine. These mutations can initiate tumourigenesis through 
several key genes in intracellular signal pathways. The inhibition of CYP2E1 (for 
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example by disulfiram, an agent used for avoidance therapy in alcohol abuse) has been 
shown to prevent chemical carcinogenesis. In CYP2E1 knockout mice, O6-MEG 
formation and colon polyp numbers decrease in response to AOM treatment (Chen & 
Huang, 2009). 
2.2.2 Mechanisms of AOM causing colon cancer 
Several activation pathways have been revealed to explain the mechanism of AOM-
induced colon cancer (Figure 2.4). These include K-ras, β-catenin and TGFβ. However, 
there is no unified explanation for the mechanism of this model.  
     K-ras: Is a small G-protein that regulates both MAPK and PI3K/Akt intracellular 
signal pathways, which in turn, regulate cell growth, proliferation and glucose 
metabolism. In K-ras pathways, K-ras plays an important role in the carcinogenesis of 
colon cancer. Azoxymethane has been shown to cause a K-ras gene transversion 
mutation from G:C to A:T at codon 12 deriving from O6-methyl-deoxyguanine adducts. 
It changes glycine to aspartic acid. This mutation causes the activation of the K-ras 
protein (Chen & Huang, 2009). 
 
 
 
Figure 2.4: Azoxymethane (AOM) mechanism of colon cancer (Chen & Huang, 2009). 
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In fact, both pathways play important roles in the carcinogenesis of many types of 
cancers including colon cancer. This is similar to human colon cancer. A study showed 
that pEGFR, pAkt and pMAPK are increased in colon tumours compared to normal 
colon tissue.  
     The PI3K/Akt pathway: Is important in understanding colon cancer as 20% of 
patients have PIK3CA mutations. The activation of PI3K/Akt can increase cell survival 
pathways via phosphorylation of downstream targets, including NFκB, and Bcl-xl. 
PI3K/ Akt also blocks p53 and the forkhead/Fas ligand to decrease apoptosis (Chen & 
Huang, 2009; Whiteside, 2007). 
. In the cell cycle pathway, PI3K/Akt deactivates glycogen synthase kinase 3 
(GSK3) and promotes cyclin D1 and myc to increase cell proliferation (Sears et al., 
2000). In the cell growth pathway, PI3K/Akt activates the mammalian target of 
rapamycin (mTOR), a conserved Ser/Thr kinase that increase’s cell size. Whether 
mToractivity is increased in the AOM model has not yet been elucidated. Downstream 
of PI3K/Akt, COX2 has also been shown to be involved in the carcinogenesis of AOM 
(Rao et al., 2002). Activated Ras stimulates the serine/threonine-selective protein 
kinase: Raf kinase, which is an oncogene. The protein encoded has regulatory and 
kinase domains. Ras binds to CR1 in their regulatory region and phosphorylates CR2, 
which is rich in serine/threonine. This leads to activation of CR3 in the kinase region. It 
then, in turn, activates MAPK and ERK kinase (MEK), which activates mitogen-
activated protein kinase (MAPK) and ERK. MAPK and ERK promote carcinogenesis 
via target proteins like c-myc, CREB, RSK, Mcl1, p16, Rb and cyclins. Inhibition of 
these pathways has been demonstrated to cause cancer cell death (Chen & Huang, 
2009). Over expression of the cell cycle promoter, cyclin D1, may contribute to the 
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AOM model as well. Cdk4 has been detected in the early stages in the AOM cancer 
induced mouse colon. 
      β-catenin pathway: β-catenin plays an important role in cell adhesion and is also an 
oncogenic protein. It associates with cadherin or a-catenin to link the actin cytoskeleton. 
It is also a co-transcriptional activator of genes in the WNT signal pathway. In its free 
form, it associates with the scaffolding proteins axin and Apc, and is phosphorylated by 
GSK-3β resulting in degradation by the proteasome. The N-terminus of β-catenin is also 
mutated in some cases, so that β-catenin cannot form the complex and be degraded. 
Thus, free β-catenin is increased and binds with the T-cell factor/lymphoid enhancer 
factor TCF/LEF to form a complex, which activates gene transcription and cell 
proliferation. It targets c-mycand cyclinD1 genes, which are well known carcinogens. 
Azoxymethane causes β-catenin mutations at codons 33 and 41, which are the serine 
and threonine residues that are targets for GSK-3β phosphorylation. This leads to the 
accumulation of β-catenin for the carcinogenesis. It has been shown that AOM 
treatment increases both β-catenin and cyclin D.  
     TGFβ pathway: Transforming growth factor-β (TGFβ) including isoforms 1, 2 and 
3 can inhibit cell growth, proliferation and the cell cycle progression and thus has an 
anti-tumour effect. Defects in TGFβ signalling have been found in 20–30% of colon 
cancer patients. The activity of the TGFβ pathway is decreased after AOM treatment, 
which mediates AOM-induced colon cancer. It has been demonstrated that the active 
form of TGFβ is decreased in AOM treated mice (Chen & Huang, 2009). 
  Montenegro (2009) cited that TGF-β induces apoptosis through several signal 
pathways. First, TGFβ forms dimers and binds to its type 2receptor. This complex then 
associates and phosphorylates its type 1 receptor. The type 1 receptor in turn 
phosphorylates receptor-regulated SMAD (R-SMAD) to cause apoptosis. Second, the 
activated type 2 receptor binds to death associated protein 6 to induce apoptosis. Third, 
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TGFβ has also been shown to inhibit the phosphorylation of the p85 subunit of 
PI3K/Akt induced by GM-CSF in several myeloid leukaemia cell lines, including MV4-
11, TF-1 and Tf-1a (Montenegro et al., 2009). 
     The evolution of colorectal cancer through the adenoma-carcinoma sequence can be 
simplified by highlighting the intervention of some of the most important markers. 
Normal epithelium, upon loss or mutation of the APC gene, is transformed into hyper-
proliferative epithelium. DNA methylation is responsible for the transformation of the 
hyper-proliferative epithelium into early adenoma. Due to the mutation of the K-ras 
gene and loss of DCC, the early adenoma is transformed into dysplastic adenoma, upon 
which the loss of p53 function results in the appearance of carcinoma. Though the 
adenoma-carcinoma sequence is a well-established concept for the development of 
colorectal cancer, it does not however, imply that all adenomas will transform into 
carcinomas since many of them may regress (Sillars-Hardebol et al., 2010).  
 In fact, the total accumulation of the genetic alterations, rather than their order 
according to a preferred sequence, is responsible for the determination of the tumour’s 
properties (Vogelstein et al., 1988). 
 The chance of long-term survival for colon, rectal, or other cancers improves 
significantly with early detection. For example, it was reported that the 5-year survival 
rate for people whose colorectal cancer is found and treated at an early stage is > 90%, 
but once the cancer has spread to nearby organs the 5-year survival rate drops to 64%, 
and it is < 10 % when the spread includes distant organs, such as the liver and lungs. 
Because the survival rates improve with early detection, considerable effort has gone 
into devising screening tests that might provide an ’early warning system‘ for 
individuals with no symptoms, as well as for those who exhibit one or more symptoms. 
It has been cited that if intermediate biomarkers are identified, one might be able to 
recognize very early stages of cancer development, long before the formation of a frank 
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tumour. With appropriate intervention, progression of the lesion could be reversed or 
slowed significantly. One promising candidate for an intermediate biomarker for colon 
cancer is known as an Aberrant Crypt Foci, or "ACF" (Wargovich et al., 2010). 
 On a much shorter time scale, Azoxymethane, PhIP and related heterocyclic 
amines generate ACF in rats when fed to them over the course of a few weeks.  
     The ACF assay also provides a quick method to screen compounds that might be 
effective at inhibiting the development of colon cancer, and several promising 
candidates for chemoprevention such as plant extracts. As mentioned elsewhere in this 
paper, the development of colorectal cancer depends on many lifestyle related factors in 
addition to genetic factors all of which influence the digestive tract. Hence, identifying 
the point at which normal colonic epithelium becomes neoplastic, hyperplastic, 
dysplastic, or an early indicator of disease is of interest to many research groups. There 
is an overwhelming idea that aberrant crypt foci (ACF) are colon cancer precursors 
(Wargovich et al., 2010), whose size and numbers directly correlate with the risk of 
developing colon cancer. 
2.3 5-Flourouracil 
5-Fluorouracil (5-FU) is still a widely used anticancer drug. Since 1957, it has played an 
important role in the treatment of colon cancer and is used for patients with breast and 
other cancers, like those of the head and neck (Grem, 2000). 5-FU is a heterocyclic 
aromatic organic compound with a structure similar to that of the pyrimidine molecules 
of DNA and RNA. It is an analogue of uracil with a fluorine atom at the C-5 position in 
place of hydrogen (Figure 2.5). Only one crystal structure is reported in the literature for 
pure 5-FU, in which the compound crystallizes with four molecules in the asymmetric 
unit and the molecule adopts a hydrogen-bonded sheet structure (Hulme et al., 2005). 
Due to its structure, 5-FU interferes with nucleoside metabolism and can be 
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incorporated into RNA and DNA, leading to cytotoxicity and cell death (Noordhuis et 
al., 2004). 
 
Figure 2.5: Chemical structure of 5-Fluorouracil (Zhang et al., 2008). 
 
2.3.1 Mechanism of action 
In mammalian cells, 5-FU is converted to fluorodeoxyuridine monophosphate 
(FdUMP), which forms a stable complex with thymidylate synthase (TS), and thus 
inhibits deoxythymidine monophosphate (dTMP) production. dTMP is essential for 
DNA replication and repair, its depletion therefore causes cytotoxicity (Longley et al., 
2003; Parker & Cheng, 1990). Dihydropyrimidine dehydrogenase (DPD)-mediated 
conversion of 5-FU to dihydrofluorouracil (DHFU) is the rate-limiting step of 5-FU 
catabolism in normal and tumour cells. Up to 80% of administered 5-FU is broken 
down by DPD in the liver (He et al., 2008). TS inhibition TS, an essential enzyme for 
catalyzing the biosynthesis of thymidylate, is implicated in the regulation of protein 
synthesis and apoptotic processes (Chernyshev et al., 2007). TS catalyzes the 
methylation of deoxyuridine monophosphate (dUMP) to dTMP, for which 5,10-
methylenetetrahydrofolate (CH2THF) is the methyl donor, and finally provides the 
reaction with thymidylate to maintain DNA replication and repair (Roberts et al., 2006). 
The reaction has a seriatim binding sequence, and dUMP binds at the active site before 
CH2THF does. Then the reaction is initiated by the nucleophilic addition of the active 
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site Cys 146 (numbering of amino acid residues used is according to the sequence of 
EcTS) to the pyrimidine C (6) atom of dUMP. Specifically, at the onset of catalysis, the 
binding position and orientation of the substrate, if correctly adopted, support an 
efficient binding of the cofactor, and then allows the formation of the ternary TS–
dUMP–CH2THF complex, and the subsequent reaction (Newby et al., 2006). Research 
has indicated that 5-FU exerts its anticancer effects mainly through inhibition of TS, for 
which the pathways have not been fully interpreted. Santi has pointed out that the 
formation of the ternary TS–FdUMP–CH2THF complex is time-dependent, and the 
reaction stops as the fluorine substituent fails to dissociate from the pyrimidine ring, 
resulting in a slowly reversible inactivation of the enzyme (Sotelo‐Mundo et al., 2006). 
Reduction of dTMP leads to downstream depletion of deoxythymidine triphosphate 
(dTTP), which induces perturbations in the levels of the other deoxynucleotides (dATP, 
dGTP and dCTP). Finally the imbalances (the ATP/dTTP ratio specifically) are thought 
to severely disrupt DNA synthesis and repair, resulting in lethal DNA damage 
(Danenberg, 1977). Accumulation of dUMP, which might subsequently lead to 
increased levels of deoxyuri-dine triphosphate (dUTP), can be misincorporated (Figure 
2.6) 
 
Figure 2.6: Mechanism of action of 5-Fluorouracil 
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2.4 Investigated medicinal plants 
The therapeutic efficacies of many indigenous plants for various diseases have been 
described by traditional herbal medicine practitioners (Natarajan et al., 2003). Natural 
products are a source of synthetic and traditional herbal medicine. They are still the 
primary health care system in some parts of the world (Singh & Singh, 2001). Fifty 
percent of the drugs in clinical usage around the world have been derived from natural 
products (Gurib-Fakim, 2006). Recent research into medicinal plants signified that new 
phytochemicals could be developed for many health problems. Multiple factors lend 
themselves to the increasing demand for herbal medicines in the last few decades, either 
due to the perception that herbs might treat and prevent diseases in a safer way than 
pharmaceutical medicines, because they are natural and therefore seen as being the 
harmless option, or because no unfavorable side effects could be identified, along with 
relatively low cost and the easy availability of herbal remedies (Stickel & Schuppan, 
2007). 
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2.4.1 Catharanthus roseus 
C. roseus (L) G. Don (Family: Apocynaceae) also known as Vinca rosea, Periwinkle, 
Nityakalyani, Billaganneru, Ainskati, Nayantra, Rattanjot, Sada bahar, Sadaphul, 
Ushamanjairi, Madagascar periwinkle, Vinca rosea or Lachnera rosea worldwide 
(Antia & Okokon, 2005) and in Malaysia known as Kemuning Cina. It is native to the 
Madagascar, Caribbean Basin, abundantly naturalized in many regions, particularly in 
arid coastal locations (Figure 2.7).  
2.4.1.1 Description  
The leaves are glossy, dark green (1-2 inch long), oblong elliptic, acute, rounded apex. 
Flowers are fragrant, white to pinkish purple in terminal or axillar y cymose clusters. 
Follicle is hairy, multi-seeded and 2-3 cm long. The seeds are oblong, minute and black. 
The plant is commonly grown in gardens for beddings, borders and for mass effect. It 
blooms throughout the year and is propagated by seeds or cuttings. The bloom of 
natural wild plants are pale pink with a purple eye in the center, but horticulturist have 
developed varieties (more than 100) with colour ranging from white to pink to purple 
(Aslam et al., 2010). 
2.4.1.2 Uses and pharmacological properties  
C. roseus has historically been used to treat a wide assortment of diseases, and as such 
is one of the most highly exploited and studied medicinal plants. European herbalists 
used the plant for conditions as varied as headaches to a folk remedy for diabetes. 
Traditionally the leaves have been soaked in water which is then drunk to ease 
menstrual pain and the leaf extract is applied to insect bites. In China, it was used as an 
astringent, cough remedy and diuretic. It was used as a homemade cold remedy to ease 
lung congestion and inflammation and sore throats in Central and South America and 
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throughout the Caribbean. An extract from the flowers has also been used to make a 
solution to treat eye irritation and infections. Finally, In India and all over the world, it 
is used as folk remedy for diabetes mellitus and this is proven by the fact that ethanolic 
extracts of leaves and flowers of Madagascar periwinkle lower blood glucose level. 
Diabetes mellitus, a major endocrine disorder affecting nearly 10% of the population all 
over the world, is possibly the world’s largest growing metabolic disease. Traditional 
plant medicines including leaves and lower parts of C. roseus are used throughout the 
world for a range of diabetic complications (Nammi et al., 2003). C. roseus has a 
variety of potential medicinal chemotherapeutic properties. It is estimated that about 
30% of all plants contain alkaloids, though C. roseus has more than 400 known 
alkaloids, some of which are approved as antineoplastic agents to treat leukemia, 
Hodgkin's disease, malignant lymphomas, neuroblastoma, rhabdomyosarcoma, Wilms' 
tumour, wound healing and other cancers (Nayak & Pereira, 2006). It can also be used 
to treat Hypoglycemia (Kar et al., 2003) as it significantly reduces the levels of protein, 
lipid peroxidation and liver (Iweala & Okeke, 2005). Its vasodilating and memory-
enhancing properties have been shown to alleviate vascular dementia and Alzheimer's 
disease (Hindmarch et al., 1991). It also has antidiabetic and hypolipidemic properties 
(Rasineni et al., 2010b), antioxidant activity (Rasool et al., 2011) and antibacterial 
activity (Raza et al., 2009).  
2.4.1.3 Phytochemistry 
Phytochemically, C. roseus contain catharanthine, serpentine, tabersonine, vindoline, 
vinblastine, and vincristine. Ajmalicine, tryptophan, tryptamine and secologanine 
(Tikhomiroff & Jolicoeur, 2002) (Figure 2.8).  
 The two classes of active compounds in Vinca are alkaloids and tannins. The 
major alkaloid is vincamine and it’s closely related semi-synthetic derivative widely is 
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used as a medicinal agent, known as ethyl-apovincaminate or vinpocetine, has 
vasodilating, blood thinning, hypoglycemic and memory-enhancing properties 
(Chattopadhyay, 1999; Chattopadhyay et al., 1991). The extracts of Vinca have 
demonstrated significant anticancer activity against numerous cell types (El-Sayed & 
Cordell, 1981). Currently, cancer is Malaysia’s number two killer, preceded only by 
cardiac disease.  
 The leaves have been known to contain 150 useful alkaloids among other 
pharmacologically active compounds which are found in the roots and stem of the plant 
(Antia & Okokon, 2005). In particular, two dimeric indole alkaloids, vincristine and 
vinblastine are valuable drugs used in the treatment of cancer of the embryonic 
membranes and acute leukaemia. They have been used as active immunosuppressive 
agents due to the inhibitory activity they induce against cells of the lymphoid line 
(Aisenberg & Wilkes, 1964), and have been used for many years as chemotherapeutic 
agents in the treatment of leukemia and Hodgkin’s disease. Other separated ingredients 
are vindolinine, vincamijine, venalstonine, tabersonine and vincubine. The crude 
alkaloids, if taken in high dosages, could be detrimental to the heart (Muhamad & 
Mustafa, 1994).  
 Catharanthine and vindoline are the most abundant alkaloids found in the C. 
roseus. This plant has been extensively studied because of the pharmaceutical 
importance of its alkaloids, vincristine and vinblastine. These two alkaloids have been 
used for many years as chemotherapeutic agents in the treatment of acute leukemia and 
hodgkin’s disease (Noble, 1990). Catharanthine and vindoline are the major monomer 
alkaloids, as well as biosynthetic precursors for vinblastine and vincristine. Other 
compounds with important biological activities that can be found in C. roseus are 
ajmalicine as anti-hypertensive and serpentine with sedative properties (Pereira et al., 
2010). 
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  High performance liquid chromatography (HPLC) has been used for the 
separation and the identification of ajmalicine, serpentine, vinblastine, vincristine, 
vindoline, catharanthine, tabersonine, lochnericine, secologanine, strictosidine, 
tryptophan and tryptamine (Noble, 1990). HPLC can be efficiently coupled to different 
detectors such as Photo Diode Array (PDA), fluorescence, ESI-MS, MS-MS, NMR and 
CD (Bringmann et al., 2002), for precise identification and/or quantification of 
alkaloids. LC-MS methods that use time-of-flight (TOF) as the detection system are of 
particular interest in herbal component analysis as TOF analyzers are well-suited to 
perform structure elucidation or confirmation. TOF instruments also provide accurate 
mass measurement and full-scan spectral sensitivity. Accurate mass measurement gives 
elemental composition of parent and fragment ions (Zhou et al., 2009) . In this study, 
the chemical constituents in C. roseus leaves and stem from three different flower 
colours that consists of pink, red and white were separated and identified by liquid 
chromatography time-of-flight mass spectrometry (LC/TOF-MS) analysis. The total-
ion-current (TIC) chromatogram was acquired in positive ion mode, and the molecular 
formula was inferred from accurate mass measurement.                             
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Figure 2.7: Catharanthus roseus  
                                      
(A) 
 
 
(B) 
 
 
 
 (C) (D) 
Figure 2.8: Chemical structure of (A) Vinocristine; (B) Vinblastine; (C) Vindoline; (D) 
Ajmalicine (O'Connor & Maresh, 2006) 
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2.4.2 Acanthus ilicifolius 
A.ilicifolius Linn. (Acanthaceae) is a spiny herb of the mangrove species, distributed 
widely throughout southeast Asia. The plant is commonly known as Holly-Leaved 
mangrove and locally known as jemuju, jeruju or daruju (Figure 2.9). 
2.4.2.1 Description  
A. ilicifolius is a strictly mangrove plant of the Acanthaceae family. It is a low 
sprawling or somewhat vine-like herb, scarcely woody and can grow up to 2m in height. 
The axes initially are erect, but tend to recline with age. Branching is infrequent and 
commonly seen in the older parts. The aerial roots tend to appear from the lower surface 
of the reclining stems. The leaves are decussating and have a pair of spines at their 
insertion. They are glabrous, gradually tapering below, either broadly lanceolate with 
entire margins or more usually with a sinuous, spiny margin. The apex is broadly 
tridentate including an apical spine. Major spines are seen at the end of leaf lobes 
horizontal or erect, minor spines between major lobes erect. The inflorescences are 
terminal spikes measuring 10-20 cm in length that extend with age. The flowers are in 
four ranks, numbering up to 20 pairs, the bract below each flower is 5mm long or 
shorter, often caduceus, with 2 lateral bracteoles, conspicuous and persistent. The 
flowers are perfect calyx 4-lobes, the upper lobe conspicuous and enclosing the flower 
in bud, the lower lobe somewhat smaller, lateral calyx lobes are narrow and wholly 
enclosed by upper and lower sepal. The corolla is zygomorphic, at least 3cm long with a 
short tube closed by basal hairs, abaxial lip broadly 3-lobed, adaxial lobes absent. There 
are 4 stamens, subequal, with thick hairy connectives, anthers medifixed, each with 2 
cells, aggregated around the style. The ovary bilocular, with 2 superposed ovules in 
each loculi style enclosed by stamens, that capitates to exposed pointed stigma. The 
fruit is a capsule measuring 2-3cm in length and 1cm in width, usually with 4 rugose 
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angular seeds measuring about 1cm in length with delicate testa, the seeds are wrinkled 
and whitish green in colour (MacKinnon, 1996). 
2.4.2.2 Uses and pharmacological properties  
In India, the plant is found in the Sundarban mangroves and is used locally for the 
treatment of rheumatism, snakebite, paralysis, asthma, ulcers, and wound healing 
(Wöstmann & Liebezeit, 2008a). 
       In Malaysia its leaves are used for rheumatism, neuralgia, and poison arrow 
wounds. In Thailand decoction of the whole plant is used for kidney stones. In Goa 
mucilaginous leaves are used as emollient in rheumatism and neuralgia. Methanolic 
extract of the leaves have been reported to exhibit hepatoprotective (Babu et al., 2001) 
and tumour reducing activities (Babu et al., 2002). Antioxidant, hepatoprotective, 
leishmanicidal, tumour reducing and anticancer activities of various extracts of A. 
ilicifolius have been reported (Babu et al., 2001, 2002), it is also reported to be resistant 
to fungi (Bandaranayake, 2002; Wu et al., 2003). 
      Anticancer activity: A study on evaluated tumour reducing and anti-carcinogenic 
activities of extracts of A. ilicifolius reported that the alcoholic extract of A. ilicifolius 
was effective in controlling tumour progression and inhibiting carcinogenisis of induced 
papilloma formation in mice. The extract showed cytotoxic activity against lung 
fibroblast cells and Ehrlich’s ascites carcinoma (EAC) cells (Babu et al., 2002; 
Chakraborty et al., 2007). 
      Anti-inflammatory activity: It also reduced protein exudation and leucocyte 
migration in the peritoneal fluid effectively inhibiting peritoneal inflammation, inhibited 
COX (1 and 2) and 5-LOX activity, and the production of pro-inflammatory cytokines 
(TNF alpha and IL-6) (Mani Senthil Kumar et al., 2008).  
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      Anti-oxidant activity: It was found that the alcoholic extract of A. illicifolius leaves 
inhibited the formation of oxygen derived free radicals (ODFR) in vitro. The methanolic 
fraction of A. ilicifolius leaf extract was found to have significant free radical 
scavenging activity (DPPH, ABTS, superoxide and hydroxyl radical). Upon 
intraperitoneal administration it was found that it augmented the endogenous 
antioxidant status (Babu et al., 2001; Mani Senthil Kumar et al., 2008).  
       Hepatoprotective activity: Oral administration of alcoholic extract of A. 
ilicifolius leaves was seen to significantly reduce carbon tetrachloride (CCl4) induced 
hepatotoxicity in rats, as judged from the serum and tissue activity of marker enzymes: 
glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT) 
and alkaline phosphatase (ALP) (Babu et al., 2001). 
      Osteoblastic activity: The methanolic extract of leaves of A. ilicifolius contained 
acancifoliuside, acteoside, isoacteroside, acanthaminoside, (+)-lyoniresinol 3a-o-b-
glucopyranoside, (-)-lyoniresinol and a-amyrin. Acteoside, isoacteoside and (+)-
lyoniresinol 3a-O-β-glucopyranoside was found to increase the growth and 
differentiation of osteoblasts significantly (Van Kiem et al., 2008).  
2.4.2.3 Phytochemistry 
The phytochemical analysis results showed that A. ilicifolius contains saponin, tannins, 
cardiac glycosides, terpenoids, flavanoids, anthraquionones, alkaloids, total flavonoid 
and total phenolic (Poornaa, 2011). A. ilicifolius has been reported in various studies as 
being a rich sources of long chain alcohols, terpenes, steroids and triterpenoidal 
saponins (Bandaranayake, 2002). 2- benzoxazolinone and acanthicifoline (Cordell, 
1999). Stigmasterol, a common plant steroid, is present in this plant in large quantity 
(Wöstmann & Liebezeit, 2008b). A phenylethanoid glycoside (ilicifolioside A), 
aliphatic alcohol glycoside (ilicifolioside B (Kanchanapoom et al., 2001b). Two lignan 
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glucosides, (+)-lyoniresinol3a-[2-(3,5-dimethoxy-4-hydroxy)-benzoyl]-O-beta-
glucopyranoside, and dihydroxymethyl-bis (3,5-dimethoxy-4-hydroxyphenyl) 
tetrahydrofuran-9 (or 9')-O-beta-glucopyranoside have been isolated from the aerial 
parts (Kanchanapoom et al., 2001b). 11-epoxymegastigmane glucoside and 
megastigmane glucosides (roseoside) have been reported from a A. ilicifolius growing 
in China (Wu et al., 2003). Blepharin (Singh et al., 2011). A new coumaric acid 
derivative acancifoliuside, acteoside, isoacteoside, acanthaminoside, (+)-lyoniresinol 
3a-O-beta-glucopyranoside, (-)-lyoniresinol, and alpha-amyrin (Huo et al., 2008). 
Protein, Amino acids (Kumar et al., 2009). Triterpenoids, alkaloids, phenolic 
compounds, lignan, flavonoid, steroids, and terpenoids (Wöstmann & Liebezeit, 2008b). 
Phytosterols (Law, 2000). Sitosterol, stigmasterol (Figure 2.10) and campesterol (Jones 
& Raeini‐Sarjaz, 2001). 
 Therefore based on the above mentioned papers, this study was undertaken in 
rats to evaluate any possible chemoprotective properties of ethanolic extracts of C. 
roseus and  A. ilicifolius against foci of aberrant crypts.  
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Figure 2.9: Acanthus ilicifolius 
 
 
(A) 
  
(B) 
Figure 2.10: Chemical structure of (A) terpenoid isopentenyl pyrophosphate; (B) 
Stigmasterol (Kamboj & Saluja, 2011) 
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2.5 Treatment of colon cancer by natural anticancer  
Cancer chemoprevention is defined as the use of a natural crude extract capable of 
inducing biological mechanisms necessary to preserve genomic fidelity (Hauser & Jung, 
2008; Pan & Ho, 2008; Umar et al., 2002). This mechanisms comprise protection 
against mutagens/carcinogens through the inhibition of uptake, activation or via 
enhanced DNA repair/replication or apoptosis (Hauser & Jung, 2008). A potential 
chemopreventive agent has to be able to prevent, inhibit, or reverse carcinogenesis prior 
to the development of the invasive disease (Krzystyniak, 2002; Pan & Ho, 2008). A 
model agent is one that has a defined mechanism of action, kills cancer cells while 
sparing normal ones, is effective in multiple sites, can be given orally, and has low cost 
and high human acceptance. These agents belong to four different classes; as alkaloids, 
the epipodophyllotoxins, the taxanes, and the camptothecin derivatives (Darwiche et al., 
2007). In 1942 the anti-cancer properties of podophyllotoxin, from the plant extract of 
Podophyllum peltatum, were discovered, but due to its high toxicity it has been ignored 
(You, 2005). In the mid-1960, semi-synthetic analogues of podophyllotoxin, etoposide 
and teniposide, were discovered and are used for the treatment of lymphomas, 
Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, acute leukemia, lung, prostate, 
bronchial, testicular and cancers (Bhutani et al., 2006; Kelland, 2005; You, 2005). 
Taxus brevifolia, Paclitaxel, and its semi-synthetic analogue docetaxel are widely used 
taxanes, a class of alkaloids that possess potent anticancer activities. While paclitaxel is 
used for the treatment of ovarian, breast, prostate, urological and bladder cancers, 
docetaxel is used for the treatment of metastatic breast, ovarian, urothelial, lung, head 
and neck, gastric and prostate cancers (Kelland, 2005; Lyseng-Williamson & Fenton, 
2005; Yusuf et al., 2003). Camptothecin (CPT), isolated in 1966 from the Chinese tree 
Camptotheca acuminate, was ignored in the 1970s due to its severe toxicity, despite its 
strong anti-tumour properties against gastrointestinal and urinary bladder tumours (Li et 
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al., 2006; Wall et al., 1966). Other plant derived compounds such as combretastatin, 
roscovitine and flavopiridol (among others) are still under clinical trials and show 
promising anticancer results (Cragg & Newman, 2005; Darwiche et al., 2007; Desai et 
al., 2008). 
 For instance, vinblastine and vincristine (vinca alkaloids) isolated from the C. 
roseus plant have been used for the treatment of hematologic cancers (Advani et al., 
2006; Cragg & Newman, 2005; Kumar et al., 2006). Vinorelbine and vindesine are 
semi-synthetic analogues of vinca alkaloids that show less toxicity and a wider range of 
anti-tumour properties when compared to vinblastine and vincristine (Darwiche et al., 
2007). Due to the fact that plants are host to many secondary metabolites that may 
provide chemoprevention against cancer, they potentially represent an almost 
inexhaustible source for the discovery of new drugs. 
2.6 Antioxidant properties of extracts in vitro and in vivo 
2.6.1 Free radicals and reactive oxygen species  
Free radicals are chemical compounds which contain unpaired electrons in their outer 
electron orbit. Free radicals are energetic and highly unstable. In order to gain stability 
they always seek other electrons to pair with, attacking and stealing electrons from other 
molecules such as lipids, proteins, DNA and carbohydrates. They can even damage 
DNA which leads to mutation and chromosomal damage. The attacked molecule loses 
its electron and becomes a free radical itself, this initiates an uncontrolled chain reaction 
that can damage the natural function of the living cell, resulting in various diseases 
(Valko et al., 2006).  
 An important incident associated with cancer and its progression is oxidative 
stress, which has been proven in many studies (Valko et al., 2006; Wiseman & 
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Halliwell, 1996).Oxidative stress results from an imbalanced intracellular production of 
ROS and antioxidant defences (Kashyap & Farrugia, 2011). 
 ROS are highly reactive due to their unstable electron configurations that 
contribute to the attraction of electrons from other molecules (Matés & Sánchez-
Jiménez, 2000). ROS includes free radicals, such as hydroxyl and superoxide radicals, 
as well as non-radicals including hydrogen peroxide and singlet oxygen (Table 2.1 ) 
Generally, ROS can be found in all aerobic cells and are generated by various 
endogenous metabolic processes such as mitochondrial respiration or exogenous source, 
which includes UV light, ionizing radiation, inflammatory cytokines, smoking, 
alcoholic beverages, food and carbonated drinks (San Miguel et al., 2011; Waris & 
Ahsan, 2006). 
Table 2.1: Reactive Oxygen Species (ROS) and their reactivity 
(Devasagayam et al., 2004). 
2.6.1.1 Role of oxidative stress in carcinogenesis 
When there is an overload of ROS concomitant with the decreased levels of 
antioxidants in the body the phenomenon is called oxidative stress. There is amble 
ROS Symbol Half-life  
(in seconds) 
Reactivity 
Superoxide O
2˙ 10-6 Generated in mitochondria, in 
cardiovascular system and others 
Hydroxyl 
radical 
·OH 10-9 Very highly reactive, generated during iron 
overload and such conditions in our body 
Hydrogen 
peroxide 
H2O2 stable Formed in our body by large number of 
reactions and yields potent species like 
·OH 
Peroxyl 
radical 
ROO· second Reactive and formed from lipids proteins, 
DNA, surges ect. During oxidative 
damage. 
Organic 
hydroperoxide 
ROOH stable Reacts with transient metal ions to yield 
reactive species. 
Singlet 
oxygen 
1
O2 10
-6
 Highly reactive, formed during 
photosensitization and chemical reaction. 
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evidence that correlates oxidative stress and antioxidant status with various malignant 
cancers, such as breast (Ray et al., 2000), prostate (Sikka, 2003), colorectal (Özdemirler 
et al., 1998) and many more (Valko et al., 2004; Waris & Ahsan, 2006). Biological 
molecules such as lipids, carbohydrates, DNA and proteins are always at risk of being 
oxidized by ROS, which leads to chronic inflammation and cancer. 
     The most striking result caused by ROS is DNA damage, which potentially leads to 
carcinogenesis. In general, cancer development is characterized by three stages: 
initiation, promotion and progression, of which ROS plays a role in all these stages 
(Steinberg, 2009). Among these three stages the promotion stage is the main line of 
ROS-related cancer promotion (Valko et al., 2006). ROS can directly produce single or 
double-stranded DNA breaks and cross-links, as well as chromosomal instability, gene 
mutations and altered gene expression (Figure 2.11).  
     The free radicals can be classified as reactive oxygen species (ROS) or reactive 
nitrogen species. ROS are the most important free radicals in our body, referring in this 
case to any free radical involving oxygen-centred free radicals containing two unpaired 
electrons in their outer shell. There are two sources of free radicals, namely endogenous 
and exogenous sources. Endogenous sources include free radicals produced during 
nutrient metabolism and energy production in the mitochondria. Another endogenous 
source of ROS, especially in the liver, is a group of enzymes called the cytochrome 
P450 mixed–function oxidase. The biochemical reactions catalyzed by the cytochrome 
P450 molecules use molecular oxygen, and during these reactions small amounts of 
ROS are generated. The extent of ROS generation may vary considerably depending on 
the compound being degraded and on the cytochrome P450 molecule involved. One 
type of cytochrome molecule that is especially active in producing ROS is known as 
cytochrome P450 2E1 (CYP2E1) (Lieber, 1997).  
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     The exogenous sources come from environmental contaminants such as smoking, 
toxic chemicals, radiation, air pollution, organic solvents and pesticides 
(Büyükokuroğlua et al., 2001). Free radicals are involved in many physiological 
processes and human diseases such as cancer, arteriosclerosis, aging, arthritis, 
Parkinson syndrome, ischaemia, toxin induced reaction, alcoholism and liver injury 
(Willcox et al., 2004). 
 
 
 
 
 
 
 
 
 
 
Chromosomal  
 
 
 
Figure 2.11: Role of reactive oxygen species (ROS) in the development of cancer 
(Klaunig et al., 2010) 
2.6.1.2 Antioxidant defence mechanisms 
Since cancer may enhance oxidative stress through various pathways, supplementation 
of antioxidants may protect against ROS and prevent damage to cells (Halliwell, 2001). 
The main characteristic of an antioxidant is its ability to trap free radicals and play a 
Damage to DNA, RNA 
protein and lipids       
Endogenous sources 
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Cytochrome P450 
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Pathogens 
ROS Oxidative Stress Antioxidants  
SNPs 
DNA repair 
Oxidative enzymes 
Carcinogenesis 
Altered gene expression 
 
Instability gene 
mutations        
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role as an electron or H
+
 donating agent (Prakash, 2001). In most cases antioxidants 
function either in preventing ROS from being formed, or else remove them before they 
can damage vital cell components (Sies, 1997; Vertuani et al., 2004). The antioxidants 
can interfere with the oxidation process by reacting with free radicals chelating catalytic 
metals and by acting as an oxygen scavenger. 
     There are two major antioxidant defence systems that can be used in order to reduce 
ROS and protect against tissue damage caused by ROS, which includes enzymatic and 
non-enzymatic antioxidants. Non-enzymatic antioxidant include vitamin C, vitamin E, 
carotenoids, thiol antioxidants (glutathione, thiol antioxidants (glutathione, thioredoxin, 
lipoic acid)) natural flavonoids, a hormonal product of the pineal gland and melatonin 
(Valko et al., 2006). Their enzymatic counterparts comprise of superoxide dismutase 
(SOD) and catalase (CAT) (Valko et al., 2006). Induction of enzymatic antioxidants is 
important for protecting against oxidative stress (Gill & Tuteja, 2010) as shown in 
(Figure 2.12 ). SOD is the most effective intracellular antioxidant, since it provides the 
first line of defence against elevated levels of ROS. SOD catalyzes the dismutation of 
O2
·
 to O2 and to the less reactive species H2O2 which is then converted to in to H2O and 
O2 by the CAT that is located in peroxisome. However, the innate defence system may 
not be effective enough for handling severe oxidative stress. It is believed that 
additional antioxidants obtained through nutrition may help counterbalance this 
problem. Mostly, the protective effects of antioxidants in the diet have been attributed to 
micronutrients such as vitamins C and E, carotenoids and plant polyphenols (Jakesevic 
et al., 2011). 
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Superoxide dismutase:   O2˙+O2·+2H
+
                  2H2O2+O2 
 
                                 Catalase:     2H2O2                   2H2O+O2 
 
Figure 2.12: Reaction catalysed by ROS scavenging antioxidant enzymes (Valko et al., 
2006) 
2.6.1.3 Role of nutrition in preventing cancer 
In the last decade, research explored a crucial role of nutrition in the prevention of 
chronic diseases especially cancer (Lobo et al., 2010). Reduced cancer risk by diet is 
reported through cancer specific mechanisms such as antioxidant activity, modulation of 
detoxification enzymes, stimulation of immunologic response, modulation of hormonal 
level and antiproliferative activities (Boffetta et al., 2010). 
 To date, dietary intervention has been extensively explored as a way to reduce 
the risks of developing colon cancer (Liong, 2008), as diet is one of the modifiable risk 
factors which have been found to influence colonic microflora and their enzymes in 
colon carcinogenesis (Gourineni et al., 2011). Waladkhani and Clemens (2001) reported 
that consumption of fruits ,vegetables, whole grains, beans, nuts and seeds contain fibre 
and biologically active phytochemicals that the human body needs to fight diseases, to 
the extent that such a diet can help to reduce the chances of colorectal cancer from 
reoccurring.  
2.6.1.4 Evaluation of antioxidant activity  
In vitro and in vivo antioxidant models were used to assess the antioxidant potential of 
the herbal extract. A great number of in vitro methods have been developed to measure 
the efficiency of natural antioxidants either as pure compounds or as plant extracts. 
Electron transfer reactions are the most famous In vitro methods, like trolox equivalent 
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antioxidant capacity (TEAC), ferric reducing antioxidant power (FRAP), α, α-diphenyl-
β-picryl-hydrazyl radical scavenging assay (DPPH), Hydroxyl radical scavenging assay, 
nitric oxide radical scavenging assay and total phenol content. These methods are 
popular due to their high speed and sensitivity. However, it is essential to use more than 
one method to evaluate the antioxidant capacity of plant materials because of the 
complex nature of phytochemicals (Chanda & Dave, 2009). 
     In addition to the in vitro assay that can be carried out on plant extracts, there are 
many in vivo cellular enzymes and compounds that may be leveraged on experimental 
animal tissue homogenate. Cells have developed a comprehensive array of antioxidants 
that act co-operatively in vivo to combat the deleterious effects of free radicals. 
Superoxide dismutase (SOD) and catalase (CAT) are considered primary antioxidant 
enzymes since they are involved in the direct elimination of ROS. SOD scavenges the 
superoxide radical (O2•-) by converting it to hydrogen peroxide (H2O2), hence reducing 
the toxic effects due to this radical or other free radicals derived from secondary 
reactions. CAT subsequently reacts with H2O2 and decomposes it into water and 
molecular oxygen (Halliwell & Gutteridge, 1986; Vattem et al., 2005). 
     A delicate balance between the generation of free radicals, endogenous and 
exogenous antioxidants is of critical importance for the physiological functioning of the 
cell. It has been proposed that a net pro-oxidant state, which occurs when there is a loss 
of homeostasis between ROS generation and detoxification, i.e. oxidative stress, results 
in lipid peroxidation and DNA damage leading to carcinogenesis (Khanzode et al., 
2003). Several reports have demonstrated that increases in the oxidant/antioxidant ratio 
are directly correlated with tumour progression, angiogenesis and migration/invasion 
(Ho et al., 2001; Kumaraguruparan et al., 2002; Nishikawa, 2008; Ścibior et al., 2008).  
 Malondialdehyde (MDA) was reported as being one of the major secondary 
oxidation products of peroxidized polyunsaturated fatty acids. It has been reported to 
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have mutagenic and cytotoxic effects (Mateos et al., 2005). MDA has been found 
elevated in various diseases that relate to free radical damage. Hence, it has been 
spectrophometrically used as a biomarker for the assessment of lipid peroxidation in 
biological and medical sciences (Mateos et al., 2005). It is a simple, sensitive and 
inexpensive method to observe the effect of oxidative stress on the levels of lipid 
peroxidation in cells; it has been adapted in biological samples, such as rat plasma, 
human plasma and urine, as well as other tissues organs such as the liver and lungs. Its 
feasibility as a biomarker for oxidative stress in vivo in a rat model has been deemed a 
success (Mateos et al., 2005). 
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METHODOLOGY  
3.1 Experimental design 
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3.2 Plants material 
3.2.1 Preparation of plant extracts 
Fresh leaves of C. roseus and A. ilicifolius were obtained from Ethno Resources Sdn 
Bhd, Selangor Malaysia, and identified by comparison with the voucher specimen 
deposited at the Herbarium of Rimba Ilmu, Institute of Science Biology, University of 
Malaya, Kuala Lumpur. The leaves were tap washed and oven dried for 7 days before 
finely ground using an electrical blender to produce 100g of fine powder from each 
plant, these were then soaked separately in 900ml of absolute ethanol in conical flasks 
for 3 days at room temperature. The mixture was filtered using a fine muslin cloth 
followed by filter paper (Whatman No1) and distilled under reduced pressure in an 
Buchi-type R-215 (Rotavapor, Switerland), then dried in a freeze-drying machine 
(LabConco, Kansas City, MO, USA) to give the crude-dried extract. The dried mass 
yielded 15.7% and 13.5% (w/w) dry weights, referring to C. roseus and A. ilicifolius 
respectively. The dry extracts of each plant were then dissolved in Tween-20 (10 % 
w/v) and administered orally to rats at a dosage of 250 and 500 mg/kg body weight. 
3.2.2 Chemicals and reagents 
Azoxymethane (AOM) was purchased from Sigma-Aldrich St. Louis, MO, USA and 
was used to induce ACF in the rat colon. All other chemicals used were of analytical 
grade and purchased mostly from Sigma-Aldrich and Fisher. AOM was dissolved in 
normal saline and injected subcutinuse to the rats at a dosage of 15mg/kg body weight 
(Marotta et al., 2003).  5-Fluorouracil (purchased from Calbiochem, USA) as a standerd 
drug was dissolved in normal salin and injected intraperitoneally to the rats at a dosage 
of 35mg/kg body weight (Srimuangwong et al., 2012). 
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3.3 Determination of antioxidant activity in vitro 
The in vitro antioxidant activity of the C.roseus and A.ilicifolius ethanolic extract was 
measured using the ferric reducing antioxidant power (FRAP), DPPH (2,2-diphenyl-1-
picrylhydrazyl) free radical scavenging activity assays, total phenolic content (TPC) and 
flavonoid content (FC). 
3.3.1 Ferric reducing antioxidant power (FRAP) assay 
The ferric reducing activity of the plant extracts were estimated using the method with 
slight modification developed by (Benzie & Strain, 1996).  
3.3.1.1 The principle 
At low pH, in the presence of antioxidants, a ferric- tripyridyltriazine (Fe III TPTZ) 
complex will be reduced to the ferrous Fe (II) and yielded an intense blue colour that 
absorbed at 593nm. 
3.3.1.2 Materials 
All chemicals were supplied by Sigma-Aldrich (Steinhem,Germany). Comprising of 
sodium acetate trihydrate, glacial acetic acid, 40mmol/L HCL, 2,4,6-tripyridly-s-triazine 
(TPTZ), iron III chloride (FeCl3), ferrous iron II sulphate (FeSO4), ascorbic acid 
(Vitamin C), quercetin, butylated hydroxytoluene 99% (BHT) and DMSO. 
3.3.1.3 Preparation of FRAP reagent 
A –Preparing the Acetate buffer (300 mM, pH 3.6): 
Glacial acid (0.4ml) added to 0.0775g of sodium acetate trihydrate, the solution was 
then made up to 25ml using distilled water. The pH of the solution was checked by 
using a pH meter. 
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B – Preparing the TPTZ solution: 
TPTZ 0.00781 g (M.W. 312.34) 10 mM was added to 0.1ml of 40 mmol/L HCL 
(M.W.36.46) and was made up to 2.5ml with double distilled water. 
C – Preparing the Ferric chloride Reagent: 
Ferric chloride 0.0135 g (FeCl3H2O) (M.W. 270.30) 20 mM was dissolved in 2.5ml of 
double distilled water. 
D- Preparing the FRAP Reagents: 
2.5 ml of reagent B and 2.5 ml of reagent C were added to 25 ml of reagent A to make 
30 ml of FRAP reagent. 
E-Preparing the standard solution: 
Dissolving 0.00278g of FeSO4.7H2O in 10ml DMSO (stock solution). 
F-Preparing the standard serial dilutions: 
The stock solution dilutes as follows to make a serial of standard solution:    
Standard concentration 
(µM) 
FeSO4.7H2O solution 
(µl) 
Distilled water 
(µl) 
Total volume 
(µl) 
0 0 1000 1000 
200 200 800 1000 
400 400 600 1000 
600 600 400 1000 
800 800 200 1000 
1000 1000 0 1000 
Which the first dilution was reagent blank 
G-Preparation of control: 
Vitamin C 0.001g, BHT, Quercetin, Gallic acid were dissolved in 1ml DMSO. 
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3.3.1.4 Preparation of crude extracts (C. roseus and A. ilicifolius) 
C. roseus and A. ilicifolius 0.001g were dissolved in 1ml DMSO separately.  
3.3.1.5 The procedure of FRAP assay 
The reaction mixture involved 300 mmol/L acetate protect, 10 mmol/L TPTZ (2, 4, 6-
tripyridyl-s-triazine) in 40 mmol/L of HCl level of acidity and 20 mmol/L of 
FeCl3.6H2O. The essential FRAP reagent was prepared clean by mixing 25ml of acetate 
protect, 2.5ml of TPTZ solution and 2.5ml of FeCl3.6H2O. The clean prepared mixture 
was incubated at 37°C in the water bath for five minutes and then a blank reading was 
taken spectrophotometrically at 593nm. After that, 10μl of extract or standard was 
introduced to 300μl of the working FRAP reagent. Absorbance was measured 
immediately upon addition of the working FRAP reagent after mixing. Thereafter, 
absorbance measurements were taken four minutes later. The standard curve was plotted 
using FeSO4 solution absorbance as standard, and the results were indicated as μmol Fe 
(II)/g dry body weight of crude extract (Appendix A1). 
3.3.2 Free radical scavenging activity (DPPH) assay 
The antioxidant activities of extracts were determined using 2, 2-Diphenyl-1-
picrylhydrazyl (DPPH) free radical scavenging assay. The assay was carried out as 
described by (Brand-Williams et al., 1995) with minor modification. 
3.3.2.1 Materials  
All chemicals were supplied by Sigma-Aldrich (Steinhem, Germany),1,1-diphenyl-2-
picryl-hydrazyl (DPPH). The chemicals comprised of acid, ascorbic acid (Vitamin C), 
quercetin, BHT, and trolex. 
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3.3.2.2 The principle 
DPPH is a molecule containing a stable free radical. In the use of an anti-oxidant which 
can offer an electron to DPPH, the purple colour which is typical for a 100 % free 
DPPH excessive decays and modifies its absorbency at 515nm which can then be 
studied. This assay measures the free radical scavenging capacity of the investigated 
extracts. 
3.3.2.3 Preparation of reagent 
 A- Preparing the DPPH reagents 
0.002g of 1, 1-diphenyl-2-picryl-hydrazyl (DPPH) dissolved in 50ml of 95% ethanol 
solution. 
B- Preparing the standard solution 
0.001g of (Vitamin C) was dissolved in 1ml DMSO, 900µl of distilled water was add to 
100µl of vitamin C, the solution was than mad up to 1000µl. 
C- Preparing the standard serial dilutions 
The stock solutions dilute as follows to make a serial of standard solution: 
Standard concentration (µg/ml) 
DPPH solution 
(µl) 
Distilled water 
(µl) 
Total volume 
(µl) 
0 0 100 0 
3.90 3.90 996.1 1000 
7.81 7.81 992.19 1000 
15.62 15.62 925 1000 
31.25 31.25 984.38 1000 
62.5 62.5 937.5 1000 
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D-Preparation of control 
0.001g of each BHT, quercetin, and trolex were dissolved in 1 ml DMSO. 
3.3.2.4 Preparation of crude extract (C. roseus and A. ilicifolius) 
0.001 g of each C. roseus and A. ilicifolius dissolved in 1 ml DMSO. 
3.3.2.5 The procedure of DPPH assay 
Briefly 0.001g from ethanolic extracts dissolved in 1ml DMSO and then serial diluted 
to get different concentrations (50, 25, 12.5, 6.25 and 3.125 µg/ml). Qurecrtine, BHT, 
and trolox were used as standard antioxidants. A quantity of (5µl) from each plant 
extract and standard were mixed with 195µl of DPPH in triplicate. The decrease in 
absorbance value was measured at 515nm after 20min intervals. The radical scavenging 
activity was calculated from the following equation and the results were expressed as: 
Mean ± Standard Error (S.E.M.) 
% of radical scavenging activity = [(Abs Blank – Abs Sample)/Abs Blank) x100]. 
3.3.3 Determination of total phenolic and flavonoid content  
3.3.3.1 Total phenolic content assay 
3.3.3.1.1 The principle 
The C. roseus  and A. ilicifolius extracts were evaluated for their total phenolic content 
by using the Folin-Ciocalteu reagent and was calculated as gallic acid equivalents in mg 
(GAE)/g of extract according to the Folin-Denis colourimetric method (AOAC, 1995).  
The reagent oxidizes phenolates (ionized phenolic) present in the sample reduces the 
acids to form a blue complex .The colour develops in a slightly alkaline environment 
which is provided by the sodium carbonate. The blue chromagen is quantified at 765 nm 
absorbance.  
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3.3.3.1.2 Materials 
All chemicals were supplied by Sigma-Aldrich and Merck (Germany), commercial 
Folin-ciocalten reagent, Sodium carbonate and Gallic acid. 
3.4.3.1.3 Preparation of reagent 
A- Preparing the 10 % Folin reagent 
10 ml of commercial Folin reagent diluted with 90ml H2O the solution was than made 
up to (1:10). 
B- Preparing the 10% sodium carbonate solution 
5.75g of sodium carbonate dissolved in 50ml distilled water. 
C- Preparing the standard solution 
Gallic acid was used as standard 
Dissolving 0.002g of Gallic acid in 1 ml DMSO (stock solution) 
D- Preparing the standard serial dilutions 
The stock solution dilutes as follows to make a serial of standard solution: 
Standard concentration (mg/ml) 
Gallic acid 
(µl) 
Distilled water 
(µl) 
Total volume 
(100 µl) 
0 0 100 100 
10 5 95 100 
50 25 75 100 
100 50 50 100 
150 75 25 100 
200 100 0 100 
 
 
 55 
 
3.3.3.1.4 Preparation of crude extract (A. ilicifolius and C. roseus) 
0.001g of each A. ilicifolius and C .roseus dissolved in 1ml DMSO.  
3.3.3.1.5 The procedure of TPC assay 
Briefly, 10µl of each standard and extract was mixed with 500 µl of Folin–Ciocalteu 
reagent. After 5 minutes, 0.35ml of sodium carbonate (Na2Co3) were added and the 
mixture was incubated at 30°C for 2 hours with intermittent shaking. The absorbance of 
the resulting blue-coloured solution was measured at 765nm and the total phenolic 
content was expressed as gallic acid equivalents mg (GAE)/g of dry weight.  
 Each test sample dilution was tested in triplicate to allow a mean absorbance to 
be calculated. TPC values of the plant crude extract were determined using the standard 
curve of absorbance versus of the concentration gallic acid equivalents (mg GAE/g). 
3.3.3.2. Determination of total flavonoids content  
The total flavonoids was determined by using the aluminium chloride colourimetric 
method and expressed as quercetin equivalents in mg (QE)/g of extract as described by 
(Dowd, 1959). Both assays were carried out in triplicate. 
3.3.3.2.1 Materials 
All chemicals were supplied by (Fisher chemicals, UK). They comprised of aluminium 
trichloride, potassium acetate (CH3COOH), quercetin and DMSO. 
3.3.3.2.2 Preparation of Flavonoid Reagent 
A- Aluminium trichloride (AlCl3) solution: 
0.5g of aluminium trichloride (AlCl3) dissolved in 5ml of distilled water. 
B- Potassium acetate solution: 
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 0.491g of potassium acetate dissolved in 5ml of distilled water. 
C- 80 % Ethanol alcohol: 
84.21ml of ethanol (95%) was added to 15.79ml of distilled water to make an 8.0% 
ethanol alcohol solution. 
D- Preparing the standard solution 
Dissolving 0.001g of quercetin in 1ml DMSO (stock solution) 
E- Preparing the standard serial dilutions 
200µl of stock solution was adding to 800µl of distilled water. 
The stock solution dilutes as follows to make a serial of standard solution: 
Standard concentration (mg/ml) 
Quercetin  solution 
(µl) 
Distilled water 
(µl) 
Total volume 
(1000µl)) 
0 0 1000 1000 
25 25 975 1000 
50 50 950 1000 
100 100 900 1000 
 
3.3.3.2.3 Preparation of crude extract (A. ilicifolius and C. roseus) 
0.001g of each A. ilicifolius and C. roseus dissolved in 1ml DMSO. 
3.3.3.2.4 The procedure of total flavonoid content assay 
Brieﬂy, 500 µl of extract was mixed with 1.5ml of 80 % ethanol, 100µl of 10% 
aluminum (AlCl3) 100µl of 1 M potassium acetate (CH3COOH), and 2.8ml of deionized 
water. 250µl of mixture was incubated at room temperature for 30 minutes and the 
absorbance was measured at 415nm. The data was expressed as milligram quercetin 
equivalents (QE)/g of extract. The total flavonoid content was expressed as quercetin 
equivalents mg (QE)/g dry weight. 
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3.4 Acute toxicity test 
Adult male and female Sprague Dawley rats (6 - 8 weeks old) were obtained from the 
Animal House, Faculty of Medicine, University of Malaya, Kuala Lumpur. The rats 
weighed between 120g–150g. The animals were given standard rat pellets and tap 
water. The acute toxic study was used to determine a safe dose for C. roseus and A. 
ilicifolius extracts. The test extracts should be administered to animals to identify doses 
causing no adverse effect and doses causing major (life-threatening) toxicity. Thirty six 
Sprague Dawley rats (18 males and 18 females) were assigned equally into 3 groups 
labelled as vehicle (10% Tween-20), low dose (2 g/kg) and high dose (5 g/kg) of C. 
roseus and A. ilicifolius extracts. The animals fasted overnight (no food, but allowed 
water) prior to dosing. Food was withheld for a further 3 to 4 hours after dosing. The 
animals were observed for 30 minutes and 2, 4, 8, 24 and 48 hours after the 
administration for the onset of clinical or toxicological symptoms. Mortality (if any) 
was observed over a period of 2 weeks. The animals were sacrificed on the 15
th
 day 
after overnight fasting. Histology and serum biochemical parameters were determined 
using standard methods (OECD, 2001). 
3.5 Animals and treatments 
Sprague Dawley healthy adult male rats were obtained from the Experimental Animal 
House, Faculty of Medicine, University of Malaya (Ethic No. PM/07/05/2012/MMA (b) 
(R). The rats were divided randomly into seven groups of 6 rats each. Each rat that 
weighed between 120g-150g was placed individually in separate wire-bottomed cages. 
The animals were maintained on a standard pellet diet and tap water. Throughout the 
experiments, all animals received human care according to the criteria outlined in the 
“Guide for the Care and Use of Laboratory Animals” prepared by the Institutional 
Animal Care and Use Committee, University of Malaya (UM IACUA). 
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 Group 1 (normal control) received subcutaneous injection normal saline, once 
weekly for 2 weeks. Normal control rats were continued on 10 % Tween-20 feeding for 
8 weeks.  
 In Group 2-5 received subcutaneous injection of AOM, 15mg/kg body weight, 
once weekly for 2 weeks.  
 Group 2 (AOM group) were continued on 10 % Tween-20 feeding for 8 weeks.  
 Group 3 (reference group) were continued on 35 mg/kg 5-Fluorouracil drug by 
intraperitoneal injection once weekly for 8 weeks.  
 Groups 4 and 5 (treatment groups) continued on 250 and 500 mg/kg for each 
plant for 8 weeks respectively.  
 The body weight of all animals were recorded once weekly for 10 weeks, and 
were sacrificed after overnight fasting by intramuscular injection of ketamine and 
xylazine anesthesia. Blood samples were collected and serum was separated for assay of 
colon biomarker. The colons were washed with cold normal saline. 
3.6 Quantification of ACF on colon mucosa grossly 
Colons were split open longitudinally cut into proximal, middle and distal portions of 
the same length. Topographic examination of the colonic mucosa with slight 
modification as Bird suggested (1995) was completed following 5 minutes fixation in 
10% phosphate buffered formalin. Colons were stained with a 0.2% methylene blue 
solution for 10 minutes, placed mucosal side up on a microscopic slide, and observed 
under a light microscope (10x). The sum of ACF in the whole colon was counted in 
each 2cm part of the colon, beginning from the distal to the proximal end of the colons. 
Aberrant crypts were differentiated from the surrounding regular crypts by their 
enlarged size, improved distance from lamina to basal surfaces of cells, as well as easily 
perceptible pericryptal zone. The variables utilized to evaluate the aberrant crypts were 
occurrence and multiplicity. Aberrant crypt multiplicity was considered as the number 
 59 
 
of crypts in every focus and classified as containing up to four or more aberrant 
crypts/focus. Under light microscopy, a microfeather scalpel blade was used to excise 
the ACF of interest and the surrounding normal crypts. 
3.7 Histopathological examination 
The Colon was fixed 24 hours in 10% buffered formalin solution for histological study. 
The fixed tissues were processed by an automated tissue processing machine (Leica 
Microsystm, Nussloch Germany). Tissues were embedded in paraffin wax by 
conventional methods. Serial Sections of 5µm thickness were cut parallel to the 
muscular mucosa using a microtome (Leica Microsystm, Nussloch Germany) and 
stained with haematoxylin and eosin (H & E) stain according to standard protocol 
(Appendix A). The histology of each ACF was assessed for crypt architecture and 
nuclear features by comparison with the normal surrounding crypts which were 
absorbed under a light microscope (Colympus, Tokyo, Japan) for histopathologyical, 
and their photomicrographs were captured with a Nokion, Tokyo, Japan). 
3.8 Biochemical and haematological analysis 
The gathered blood samples were centrifuged at 2500 rpm for 15 minutes subsequent to 
being completely clotted. Serum for assay of biochemical parameters such as albumin, 
total protein, urea and lactate dehydrogenase and EDTA blood samples for assay of 
haematological parameters such as Hb and WBC were examined spectrophotometrically 
by normal standard automated techniques according to the procedures described by the 
manufacturer in Central Diagnostic Laboratory (CDL), University of Malaya Medical 
Centre.  
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3.9 Estimation of antioxidant in colon tissue 
Colon samples were rinsed instantly with ice cold saline to take away as much blood as 
possible. Colon homogenates (10% w/v) were arranged in a cold 50 mM PBS (pH 7.4) 
using homogenizer in ice (Wise mix HG-15,Daihan scientific, seoul, Korea). The cell 
particles were eliminated by centrifugation in a refrigerated centrifuge at 4500rpm for 
15 minutes at 4°C using a refrigerated centrifuge (Rotofix32 Hettich Zentrifuge, 
Germany). The supernatant was used for the estimation of the following in vivo 
antioxidant, using commercially available kits from (Cayman Chemical Company, 
USA): Malondialdehyde (MDA) or thiobarbituric acid reactive substance (TBARS) (cat 
# 10009055), Superoxide Dismutase (SOD) (cat # 706002) and catalase (CAT) (cat # 
707002) Appendix B. All assays were performed as directed by the producer’s manual. 
Protein concentration was determined by the Bardford method using bovine serum 
albumin as a standard. 
3.9.1 Malondialdehyde (MDA) 
3.9.1.1 Principle 
The MDA-TBA adducts formed by the reaction of MDA and TBA under high 
temperature (90 - 100 °C) and acidic conditions is measured colorimetrically at 530-540 
nm and an emission wavelength of 550 nm. 
3.9.1.2 General procedure 
The assay was performed by add 100 µl of the sample ,100 µl stand SDs solution and 4 
ml of the colour Reagent .The reaction were initiated by boiling 1hour. To stop the 
reaction incubate on ice for 10 min, than centrifuge 10 min and adding 150µl to all the 
wells being used. The absorbance reading was taken at 530-540nm.   
The MDA activity was determined by using the following formula: 
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MDA (µM) = (Corrected absorbance)-(y-intercept)) 
              Slop 
3.9.2 Superoxide dismutase (SOD) assay 
3.9.2.1 Principle 
One unit of SOD is defined as the amount of enzyme needed to exhibit 50 % 
dismutation of the superoxide radical. Its measures all three types of SOD (Cu/Zn, Mn 
and FeSOD). 
 
Xanthine+O2                                      2O2                                Formazan dye 
                                         Xanthine oxidase      
H2O2 Uric acid                                   2O2                                 Tetrazolium salt 
                           
                
                  O2+H2O2 
3.9.2.2 General procedure 
The assay was performed by adding 200 µl of the diluted radical detector and 10 µl of 
sample to wells .The reactions were initiated by adding 20 µl of diluted Xanthine 
Oxidase to all the wells being used. The plate was incubated for 20 minutes at room 
temperature and the absorbance reading at 440 nm. The SOD activity was determined 
by using the following formula: 
SOD (U/ml) = (sample LR-y-intercept × sample dilution 
Slope 
SOD 
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3.9.3 Catalase assay 
3.9.3.1 Principle 
Catalyses conversion of two molecules of H2O2 and two molecules of water (catalytic 
activity).it also demonstrates peroxidatic activity, in which low molecular weight 
alcohols can sever as electron donors.  
 
 (Catalytic Activity)         2H2O2             Catalase             O2 + 2H2O 
 (Peroxidatic Activity)    H2O2 +AH2     Catalase                A + 2H2O 
3.9.3.2 General procedure 
The assay was performed by add 100 µl of the Assay buffer, 30 µl of methanol, and 20 
µl of the sample. The reaction was initiated by adding 20 µl of Hydrogen Peroxide. To 
terminate the reactions adding 30 µl of potassium Hydroxide and 30 µl of purpled 
(chromagen), than incubate for 10 minutes at room temperature, finally adding 10 µl of 
Potassium Periodate .The absorbance reading was taken at 540 nm.   
The formaldehyde concentration of sample was determined by using the following 
formula: 
Formaldehyde (µM) = (Sample absorbance)-(y-intercept) × 0.17 ml 
                                                   0.02 ml                         Slop 
The Catalase activity was determined by using the following formula: 
CAT Activity = µM of sample × Sample dilution= nmol/min/ml 
                                                  20 min 
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3.10 Immunohistochemistry  
Colon biopsies were fixed in buffered formalin and were processed by a tissue 
processing automated machine. Colon specimens were embedded with paraffin. 
Sections (3-5 µm) used poly-L-lysine-coated slides, colon sections were prepared and 
heated in an oven (Venticell, MMM, Einrichtungen, Germany) for 25 minutes at 60
o
C. 
After heating, colon sections were deparaffinized in xylene and rehydrated in graded 
alcohol. Concentration of 10mM sodium citrate buffer was boiled in a microwave for 
antigen retrieval.  
 Immunohistochemistry staining steps were performed following the manual’s 
instructions (DakoCytomation, USA). In brief, 0.03% hydrogen peroxide sodium azide 
was used to block the endogenous peroxidase for 5 minutes, followed by washing the 
tissue sections gently with a wash buffer and then incubated with Proliferating Cell 
Nuclear Antigen (PCNA) (1:200) (Santa Cruz Biotechnology Inc, California, USA) 
biotinylated primary antibodies for 15 minutes. After incubation, sections were gently 
re-washed with a wash buffer and kept in the buffer bath in a humid chamber. 
Streptavidin-HRP was then added and incubated for 15 minutes followed by washing. 
Diaminobenzidine-substrate chromagen was added to the sections and incubated for 
over 7 minutes followed by washing and counterstaining with hematoxylin for 5 
seconds. The sections were then dipped 10 times in weak ammonia (0.037 mol/L), 
washed and then cover slipped. Light microscopy was used to examine the brown-
stained positive antigens. The PCNA labeling index (PI) was computed as the [(number 
of positive cells) / (total number of epithelial cells)] X 100 for each field.  
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3.11 Real-time quantitative polymerase chain reaction analysis 
3.11.1 Reagents 
RNAlater, RNeasy plus Mini Kits, QIA shredder homogenizer, Mortar and pestle,  
50%-100% ethanol. 
3.11.2 General procedure 
From the tissue colon mucosa of normal saline injected rats, AOM-injected rats, 5-
Flurouracil-treated AOM-injected rats and of A. ilicifolius and C. roseus-treated AOM-
injected rats colon samples were placed immediately into RNAlater solution (Ambion, 
USA), incubated over night at 4C and stored at -80oC. Total RNA was isolated 
according the manufacturer’s instructions using RNeasy plus Mini Kits (catalogue 
No74134, Qiagen, Germantown, Maryland, USA). 
 RNA was extracted using the RNeasy-Plus Mini kit according to the 
manufacturer’s protocol, at a weight of 30mg rat tissue and disruption of the tissue 
being done via a mortar. To hemogenize tissue 600µl of Buffer RLT was added directly 
to each mortar. The tissues then became lysate. The lysate was collected into a 
microcentrifuge (QIA shredder) tube and centrifuged twice for 2 minutes and 3 minutes 
respectively at maximum speed. The resultant lysate was then filtered passed a DNA 
eliminator spin column and centrifuged for 30 seconds at ≥ 8000 x g ≥ (10,000 rpm). 
50% ethanol was added to the homogenized lysate in a1:1 ratio and mixed using 
pipetting. 600μl of the sample, including any precipitate that may have formed, was 
transferred to an RNeasy spin column placed in a collection tube and centrifuged for 15 
seconds at ≥ 8000 x g. Successive aliquots of any excess of the sample were centrifuged 
in the same RNeasy spin column. Flow-through was discarded after each centrifugation. 
After all the samples had been loaded, 600μl of Buffer RW1 was added to the RNeasy 
spin column and centrifuged for 15 seconds at ≥ 8000 x g to wash the spin column 
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membrane. Flow-through was discarded and 500μl of Buffer RPE was added to the 
RNeasy spin column and centrifuged for 15 seconds at ≥ 8000 x g. Flow-through was 
discarded and this step was repeated for a longer centrifugation time of 2 minutes. 
RNeasy spin column was then placed in a new 1.5ml collection tube and 25μl of RNase 
free water was added directly to the membrane. The column was centrifuged for 1 
minute at ≥ 8000 x g to elute the RNA. This step was repeated using another 25μl of 
RNase free water. All steps were performed at room temperature from the worn out 
mucosa of the treated and untreated rats. RNA concentrations were measured by a Nano 
Drop ND-2000 spectrophotometer (Thermo Fisher, USA). RNA quality and integrity 
were concluded through the A260/A280 ratio and agarose gels electrophoresis 
respectively.  
3.11.3 RNA agarose gel electrophoresis 
3.11.3.1 Reagents 
Ethidium Bromid (BASE), agarose gel, bromophenol blue loading dye, Tris-Borate 
EDTA buffer. 
3.11.3.2 Principle 
The integrity and size distribution of total RNA purified with QIAamp RNA pulse Mini 
Kits was checked by denaturing agarose gel electrophoresis and ethidium bromide 
staining through the use of agarose gel electrophoresis apparatus (Bio-Rad, Richmond, 
CA, USA). The apparent ratio of 28S RNA to 18S RNA should be approximately 2:1. 
The extracted RNA was stored at −80ºC until used. 
3.11.3.3 General procedure 
Agarose (0.5g) was dissolved in a Tris-Borate EDTA buffer (50ml; TBE) by heating in 
a microwave until boiled, this solution was then allowed to cool before ethidium 
bromide was added (0.5µl). Gels (0.25%) were then cast in a 10 x 20 cm gel tank, any 
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bubbles were removed with a pipette tip and then gel comb was added before allowing 
the gel to set. Gel electrophoresis was carried out in a horizontal tank first containing 
then loading the Gel by Mix reaction volumes onto a piece of parafilm, at the 
appropriate volumes of 3µl loading dye onto parafilm with 2µl of each sample. Once 
the appropriate volume of sample and mix are prepared to make up the 5µl sample, they 
were slowly and carefully placed into the well. TBE buffer was run at 95V for 45 
minutes. Migration of the bands was monitored by visualizing bromophenol blue. Gels 
were imaged using the Typhoon 9410 Variable Mode Imager. The gel was then 
carefully exposed to UV trans-illuminator. The bands are analysed and pictures of the 
results are taken.  
3.11.4 Reverse transcription and cDNA synthesis 
3.11.4.1 Principle 
One microgram of total RNA was converted to cDNA using High capacity RNA-to-
cDNA reagent from Applied Biosystems, USA.  
3.11.4.2 Reagents 
High Capacity RNA-to-cDNA Master Mix, nuclease-free water. 
3.11.4.3 General procedure 
The High Capacity RNA-to-cDNA Master Mix kit (Applied Biosystems, USA) was 
used for cDNA synthesis. The kit uses the random primer scheme for initiating cDNA 
synthesis. Random primers ensure that the first strand synthesis occurs efficiently with 
all species of RNA molecules present, including mRNA and rRNA. Reverse 
transcription of RNA was carried out in a 20μl final volume using 1000ng total RNA. 
The measured RNA concentration values were calculated and 1X RT Master mixture 
was prepared as shown in (Table 3.1) below.  
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Table 3.1: making the 1X Reverse Transcription (RT) Master Mix for cDNA synthesis 
Reagent Volume per Reaction Final conc 
Master Mix  4_µl 1x 
RNA 
--µl (Variable (up to 16 μl), calculated according to 
RNA concentration in order to obtain 1μg cDNA 
per reaction  
10pg- 1µg-
1000 ng 
Deionized water --µl - 
Total volume 20µl - 
 
Referring to the table, the volume of master mix needed to prepare one sample is 
indicated to the left, from which the required numbers of reactions, for instance 20µl 
total, were calculated. This calculation also included additional reactions to provide 
excess volume for the loss that occurred during reagent transfers.  
 4μl of 1X RT master mix was added into each tube containing 1000ng of RNA 
sample before adding deionized water (total volume of RNA with deionized water 
16µl). The content was mixed by pipetting up and down before the tubes were 
centrifuged for a short period (1 minute) in order to spin down the contents and to 
eliminate any air bubbles. The tubes were placed on ice until loading on the thermal 
cycler conditioner (PTC-100 Programmable Thermal Controller, MJ, USA) as shown in 
(Table 3.2). 
Table 3.2: Thermal cycler condition steps 
 Step1 Step2 Step3 Step 4 
Temperatur
e 
25 °C 42°C 85°C 4°C 
Time 5 min 30 5 
Hold to 
4°C 
Event 
Random primers to 
RNA 
cDNA 
synthesis 
Inactivation of 
enzymes 
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The cDNA product was stored at -20°C. All the above steps were performed on ice and 
a nuclease free bench. 
3.11.5 Real- time quantitative reverse-transcriptase polymerase chain reaction 
analysis 
3.11.5.1 Procedure  
The cDNA synthesis was used as suggested by the manufacturer. RT-PCR was carried 
out by ABI TaqMan gene expression assays for Bcl-2, Bax and p53. 
3.11.5.2 Reagents  
ABI TaqMan gene expression assays Tbp (assay ID: Rn01455646_ml), HPRT1 (assay 
ID: Rn01527840_ml), Bcl-2 (assay ID: Rn99999125), Bax (assay ID: Rn02532082), 
and P53 (assay ID: Rn00755717), TaqMan Fast Advanced Master Mix reactions, 
nuclease-free water. All reagents and genes applied from Applied Biosystems, USA. 
3.11.5.3 General procedure  
To make a standard curve, 20μl of each sample with RT was used to make a cDNA 
pool. From this cDNA pool, 10μL was taken out and diluted 1:2 as shown in (Table 3.3) 
below: 
Table 3.3: Standard curve dilution for real time PCR 
Dilution 
 
1:2 10µl of pooled sample+10µl dH2O 
1:5 5µl (of 1)+ 25µl d H2O 
1:5 5µl (of 2)+ 25µl d H2O 
1:5 5µl (of 3)+ 25µl d H2O 
1:5 5µl (of 4)+ 25µl d H2O 
 
The samples are dilution same as standard dilution  
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3.11.5.4 Prepare the PCR reaction mix 
Table 3.4: Components volume and concentration used in the RT-PCR reaction mix 
(total volume 10 μl) 
Component 
96-well plate Volume (μl) 
for 1 reaction 
Final concentration 
Master Mix 5.0 1x 
Gene Expression 0.5 1x 
cDNA 1.0 100 ng to 1 pg 
Nuclease free water 3.5 - 
Total volume per reaction 10 - 
 
Both standard and samples were placed on ice. 
According to the protocol guidelines, all samples were run in triplicate in total reaction 
volume 30µl: 15μl master mix, 1.5µl TaqMan gene expression assay 3µl cDNA and 
10.5 µl nuclease-free water. Quantitative real-time RT-PCR was done using TaqMan 
fast advanced master mix (Applied Biosystems, USA) and the step one plus Real-Time 
PCR system (Applied Biosystems, USA) in triplicate wells. Cycle parameters were as 
follows: activation at 95°C for 20 s, 40 cycles of denaturation at 95°C for 1s, and then 
annealing and extension at 60°C for 20s. The data was analysed by utilising a 
comparative threshold cycle (Ct) technique. Gene expressions were calculated using the 
Gene Ex software (MultiD Analyses AB, Sweden). The corresponding mRNA level 
from colonic mucosa of the normal group (calibrator) was used as an external reference. 
The levels of Hprt1 (assay ID: Rn01527840) and Tbp (assay ID: Rn01455646) mRNA 
were used as an internal reference to standardize the data. The fold changes of each 
mRNA (mRNA relative expression) were expressed relatively to the mean value of the 
related mRNA located in the mucosa of the normal control rats, and was calculated 
using the 2
-∆∆Ct
 method (Livak & Schmittgen, 2001). Statistical analysis of differences 
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was performed by a two-tailed unpaired Student’s t test. A p value of <0.05 was 
considered indicative of a statistically significant difference. 
3.12 Chromatography materials 
Silica gel 60 powder (0.063 - 0.200 mm) and 70 - 230 mesh (Merck, Darmstadt, 
Germany), HPLC grade hexane, HPLC grade ethyl acetate, HPLC grade methanol, 
HPLC grade acetonitrile were purchased from Merck, Germany. 3.0 x 50 cm Kontes 
Scientific Glassware (Vineland, NJ, USA) connected with an EYEL-4 pump (Tokyo 
Rikakikai, Tokyo, Japan). 
3.12.1 Profiling and fractionation of crude extracts  
The ethanol crude extract of both plants (1g) were subjected to column chromatography 
fractionation using 3.0 x 50 cm glass columns packed with silica gel G60 powder 
(0.063-0.200) and (70–230) then connected with an EYEL-4 type pump. The crude 
extracts were eluted stepwise with gradients (25ml each time at five different 
concentrations; 20, 40, 60, 80 and 100 %) of different solvents in the order of increasing 
polarity, starting with the least polarity towards the higher polarity. The solvents used 
were hexane, ethyl acetate, methanol, acetone, acetonitrile and water. All fractions were 
collected in clean tubes and all eluents were then pooled to give six major fractions 
(Fraction 1–8). The solvents were then evaporated under reduced pressure in a 
centrifuge evaporator and freeze dryer (Awaad et al., 2008). All fractions and crude 
extracts were then subjected to an in vitro chemoprotective cell line assay, and then 
given positive result identification through the use of high performance liquid 
chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS) to 
know the active constituents. 
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3.13 Thin layer chromatography 
3.13.1 Principle  
Thin layer Chromatography (TLC) is a solid-liquid technique consisting of two phases, 
those being the solid phase (stationary phase) and liquid phase (mobile phase). The 
most commonly used solid in TLC are silica gel. In this case silica gel 60 F254 plate, 
20x20 cm, 0.2 mm (Merck, Darmstadt, Germany) was used. 
 TLC is a sensitive, fast, simple and inexpensive analytical technique. It's used to 
determine the number of components in a mixture and to identity the RF values of 
substances 
3.13.2. General procedure 
All collected fractions from column chromatography banded on TLC aluminum sheets 
coated with silica gel 60. The sheets were developed in a TLC tank using five various 
compositions of solvent (hexane, isopropanol, methanol, acetonitrile, acetic acid) the 
sheets were than visualized under ultraviolet lamps (254nm short wave and 366nm long 
wave). The isolation of the compounds was monitored by TLC using mixtures of ethyl 
acetate and methanol. The bands were circled using a pencil and respective RF values 
were calculated as follows: 
Rf = x/y      where x= distance travelled by sample in cm 
Y= solvant front in cm 
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3.14 Cytotoxicity and anticancer activity 
3.14.1 Cells and chemical  
Human colorectal carcinoma cell lines HT-29 and normal colon epithelial cell line 
(CCD841) were purchased from ATCC, USA. RPMI 1640 cell culture media, Fetal 
Bovine Serum (FBS) and penicillin/streptomycin solution were purchased from (Sigma-
Aldrich, Gillingham, UK). Trypsin EDTA solution, trypan blue, MTT (3-(4,5-dimethyl 
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide), sterile tissue culture flasks and 
analytical grade ethanol were purchased from (Merck, Germany). Sterile cell culture 
plates, sterile centrifuge tubes, phosphate buffer saline and dimethyl sulfoxide reagent 
were purchased from (Sigma Aldrich, Germany). Cell culture flasks and plates were 
purchased from (Jet Biofil). Hemocytometer (Weber, Teddington, UK). Cell culture 
work was done under sterile conditions in class II bio-safetycabinat (ESCO, USA). 
3.14.2 Cytotoxicity procedure 
For the estimation of the cytotoxicity and potential anticancer activity of both plant 
fractions, an established MTT assay as described by (Mosmann, 1983) was used with 
two cell lines. Human colorectal cancer cell line (HT-29) and normal colon human cell 
line (CCD841) were grown in RPMI medium supplemented with 10% FBS (Sigma-
Aldrich, USA) and 1% penicillin-streptomycin solution. Both cell lines were cultured at 
37°C in a humidified 5% CO2 incubator, and sub-cultured twice weekly using 
trypsin/EDTA. The MTT assay was carried out for eight fractions for C. roseus and two 
fractions for A. ilicifolius, with the assay being performed in triplicates in three 
independent experiments.  
 The effect of the extracts on human cell HT 29 and (CCD841) were determined 
by using MTT assay as described by Mosmann and Scudiero using MTT reagent 
(5mg/ml) (Mosmann, 1983; Scudiero et al., 1988). Briefly, 100µl of the isolated HT 29 
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suspension were cultured in 96-well flat bottom microtiter plates at 5 × 10
4 
cells/ml in 
RPMI medium containing 10% (v/v) FBS and incubated at 37°C, 5% CO2 and 90% 
humidity incubator for 48 hours. On the second day, the cells were treated with 20µl of 
two fold serial dilution with final concentration (166.6, 83.3, 41.7, 20.8 µg/ml) of 
fractions and re-incubated at 37°C in a humidified 5% CO2 incubator for 24 hours. After 
48 hours, 10µl of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
a tetrazole) was added into each well in the plates and again re-incubated for four hours 
at 37°C in a humidified 5% CO2 incubator. The yellow MTT is reduced to purple 
formazan in the mitochondria of living cells (Mosmann, 1983). Approximately 80µl of 
medium with MTT was removed from all wells and 100µl of Dimethyl sulfoxide 
(DMSO) was added to each well to dissolve the insoluble purple formazan product into 
a coloured solution. The absorbance of this coloured solution measured at 595nm using 
power wave x340 ELISA Reader (Bio-Tek Instruments, USA). The assay was 
performed in triplicates in three independent experiments.  
 The identification and characterization of active compounds were performed by 
LCMS. 
3.14.3 Identification of active constituents  
In this study liquid chromatography-mass spectrometry (LC-MS) was used for 
identification of phenolics, alkaloids and other active constituents in the fractions that 
give positive result identified by the in vitro anticolon cancer activity assay i.e., C. 
roseus fractions 5 (F 5) and A. ilicifolius fraction 3 (F 3). The identification and 
characterization of isolated compounds from active fractions were performed by 
comparing ultraviolet (UV) and mass spectrometry (MS) as described by (Lin et al., 
2008). The components of fractions such as phenolics showed positive mass spectra 
containing intense [M+H] ions as well as fragmented ions created after the cleavage of 
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compound bonds. The method development and optimization were done by the 
technician at BST consultancy and services Sdn Bhd.  
3.14.3.1 Principle 
3.14.3.2 Sample preparation 
The sample was prepared by dissolving 2mg in 2ml methanol inside a volumetric flask. 
The solution was then filtered by using SRP-4 membrane 0.45 mm. Stock solution 1 
mg/ml was kept in a fridge at 4°C. 
3.14.3.3 Instrumentation and parameter used equipment 
Acquity
 
ultra performance liquid chromatography (UPLC)-PDA system coupled to a 
Synapt High Definition Mass Spectrometry (HDMS) quadrupole-orthogonal 
acceleration time-of-flight (TOF) detector (Waters Corporation, USA) equipped with an 
ESI source (Table 3.5). 
Column: Acquity BEH C18, 2.1 x 50 mm, 1.7 μm UPLC column 
Injection volume: 3 l 
Mode: Positive ESI mode 
Solvents: A: Water + 0.1% Formic acid B: Methanol+ 0.1% Formic acid 
Flow rate: 0.5ml/min 
Gradient:  
Table 3.5: UPLC and LC-MS gradient conditions 
Time % H2O+ Formic Acid % MeOH 
0.00 100 0 
0.83 60 40 
2.50 55 45 
3.33 50 50 
3.75 50 50 
4.17 20 80 
4.25 100 0 
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3.15 Statistical analysis 
The statistical significance was assessed using one-way analysis of variance (ANOVA) 
followed by Bonferroni’s multiple comparison post Hoc test. All values were expressed 
as mean ± S.E.M. and a value of P <0.05 was considered significant as compared to the 
respective control group using SPSS programme for windows version 17.0 (SPSS Inc. 
Chicago, IL, USA). 
Real-time RT-PCR data exported form “Step One Plus” software to Ms. Excel where all 
results arranged in one study and finally analysed by using GenEx program version 5.4 
(GenEx software, www.multid.se), fold changes were calculated and T-test was used to 
examine the difference between groups for all genes and P ˂ 0.05 was considered as the 
level of significance. 
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RESULTS 
4.1 Antioxidant activity of C. roseus extract in vitro 
4.1.1 Ferric-reducing antioxidant power (FRAP)  
The FRAP value of the C. roseus extract was determined to be 471.9 ± 0.274 µmol 
FeII/g. (standard curve equation: y = 0.0006x + 0.0013, R
2
= 1) as shown in appendix 
A1. The FRAP result of C. roseus is comparable to that of BHT. Ascorbic acid, 
quercetin and gallic acid were used as reference compounds and their FRAP values 
were calculated to be 521.4 ± 0.82, 1181.9 ± 0.274, 2267.1 ± 0.55 and 2640 ± 0.277 
µmol Fe II/g respectively, which was almost the same as that of the standard BHT, but 
significantly lower than that of ascorbic acid, quercetin and gallic acid. There are 
statistical differences between C. roseus and these standards, with the results shown in 
(Figure 4.1). 
 
Figure 4.1: Ferric-reducing antioxidant power (FRAP) of C. roseus. All values are 
expressed as mean ± SEM. Mean with different letters indicate significantly different 
values P< 0.05.BHT; Butylatedhydroxyl toluene. 
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4.1.2 Scavenging activity of C. roseus extract (DPPH) 
Antioxidant activity is measured as the capacity of the tested compound to reduce the 
stable DPPH radical. The scavenging capability increases with the increase in 
concentration of the C. roseus as shown in (Figure 4.2). The IC50 value represents the 
concentration needed to cause 50% inhibition of DPPH. Different concentrations of the 
extracts, as well as BHT, quercetin and trolox were used and the IC50 values were 
determined to be 47.20µg/ml for C. roseus, 17.40µg/ml for BHT, 7.40µg/ml for 
quercetin and 6.20µg/ml for trolox (standard curve equation: y = 1.2997x + 0.1834, R
2
= 
0.997) as shown in appendix A2. 
 
Figure 4.2: Scavenging Activity of C. roseus extract (DPPH). All values are expressed 
as mean ± SEM, P< 0.05. 
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4.1.3 Total phenolic and flavonoids content 
Total phenolic content of the ethanolic extract of C. roseus was determined to be 
appreciable amounts of phenolic compound to 113.81 ± 0.027 mg (Gallic acid 
equivalent) per g of extracts, with standard curve equation: y = 0.0007x + 0.0015, R
2
= 
0.989 as shown in Appendix A3. 
 The total Flavonoids value was 56.97 ± 0.008 mg (Quercetin equivalents) per g 
of extract (standard curve equation: y = 0.0054x + 0.005, R
2
= 0.999) as shown in 
appendix A4 with a ratio flavonoids/phenolic of 0.50. Thus, phenolic compounds were 
the predominant antioxidant components in C. roseus extract, which leads to more 
potent radical scavenging effect. 
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4.2 Acute toxicity study  
Acute toxicity study is an experimental study in which selected rats are treated with the 
C. roseus extract at a dose of 2g/kg and 5g/kg. The rats were closely observed for a 
period of 14 days. At the end, it was found that all the rats were alive and did not show 
any noticeable significant toxicity at these doses. Both biochemical and histological 
indicators showed no hepatic or renal toxicity. The finding from the applications of the 
C. roseus extract to the control rats provided sufficient evidence to conclude that the 
orally administered extract was safe and presented no extract-related toxicity even at the 
highest dose of 5g/kg as shown in (Table 4.1, Table 4.2 and Figure 4.3). 
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                             Table 4.1: Effects of C. roseus extract on kidney biochemical parameters in acute toxicity 
Dose 
Sodium 
(mmol/L) 
Pottasium 
(mmol/L) 
Chloride 
(mmol/L) 
CO2 
(mmol/L) 
Anion gap 
(mmol/L) 
Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
Vehicle (10% 
Tween-20) 
142.05 + 0.58 4.89 + 0.07 104.01 + 0.87 24.85 + 0.55 18.11 + 0.58 5.50 + 0.38 34.88 + 2.38 
LD C. roseus  
(2 g/kg) 
142.03 + 1.54 5.00 + 0.06 106.13 + 1.03 22.60 + 1.19 18.17 + 0.61 6.20 + 0.50 33.67 + 2.65 
HD C. roseus  
(5 g/kg) 
142.50 + 0.86 4.95 + 0.05 105.17 + 0.58 23.96 + 1.05 18.52 + 0.45 5.63 + 0.494 34.51 + 4.90 
                          Values expressed as mean ± SEM. There are no significant differences between groups P< 0.05. 
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  Table 4.2: Effects of C. roseus extract on liver biochemical parameters in acute toxicity 
Dose 
T.protein 
(g/L) 
Albumin 
(g/L) 
Globulin 
(g/L) 
T.b 
(µmol/L) 
Cb 
(µmol/L) 
Alp 
 (IU/L) 
ALT 
 (IU/L) 
AST 
(IU/L) 
GGT 
(IU/L) 
Vehicle (10% 
Tween-20) 
61.13 + 1.08 9.16 + 0.53 51.39 + 1.33 2.13 + 0.17 1.00 + 0.00 153.07 + 15.01 50.81 + 1.71 173.53 + 7.17 3.17 + 0.16 
LD C. roseus  
(2 g/kg) 
58.97 + 0.48 8.67 + 0.33 49.73 + 0.69 2.11 + 0.15 1.00 + 0.00 156.33 + 15.24 48.02 + 0.88 178.18 + 5.84 3.67 + 0.42 
HD C. roseus  
(5 g/kg)   
60.04 + 1.03 9.70 + 0.47 50.08 + 1.05 2.08 + 0.10 1.00 + 0.00 155.17 + 9.09 46.52 + 1.76 175.87 + 8.55 3.17 + 0.17 
Values expressed as mean ± SEM There are no significant differences between groups P< 0.05. Tb: Total bilirubin; Cb: Conjugated 
bilirubin; Alp: Alkaline phosphatase; ALT: Alanine aminotransferase: AST: Aspartate aminotransferase: GGT: G-Glutamyl Transferase. 
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Figure 4.3: Histological sections. Effect of C. roseus on liver and kidney on acute 
toxicity test (H & E stain; 20x). 
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4.3 Analysis of body weight 
The body weight of all rats were taken at the beginning (week 1) of the experiment, then 
weekly up to 10 weeks (Figure 4.4). Although there is a difference between groups, 
statistically there were no significant differences in the body weight among the groups. 
 
Figure 4.4: Effect of C. roseus on body weight of rat’s in different experimental 
groups. All values expressed as mean ± SEM. No significant changes in body weights 
were observed in all rat’s group P < 0.05. 
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4.4 Efficacy of C. roseus on ACF formation 
ACF were mostly observed in the middle colon. ACF present in the colon were counted 
and the average of the total number of ACF and the number of crypts per focus was 
obtained. ACF were observed in the colon as well as in multicrypt clusters (more than 
four crypts/focus) of aberrant crypts (Table 4.3 and Figure 4.5). Rats treated with AOM 
and fed with the low and high dose of C. roseus extract showed a significant reduction 
of total ACF/colon compared with the AOM-control rats 65% and 61% inhibition 
respectively, P<0.0001. The incidence of multiple aberrant crypts/focus was also 
significantly inhibited in rats fed with C. roseus when contrasted with the AOM-
induced rats.  
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Table 4.3: Effect of C. roseus on AOM-induced colonic ACF containing four or more aberrant crypts in rats 
Groups 1 crypt 2 crypts 3 crypts 4 crypts 
5&more 
crypts 
Total ACF 
inhibition 
% 
AOM control 19.50 ± 3.62 29.79 ± 4.89 23.04 ± 2.70 24.67 ± 2.22 34.33 ± 4.94 131.33 ± 15.09 0 
5-Fluorouracil 10.16 ± 1.04 9.50 ± 2.04* 7.91 ± 0.69** 6.25 ± 0.81** 7 ± 0.64** 40.83 ± 3.06** 69% 
LD 250 mg/kg 
C .roseus 
15.66 ± 3.27 9.50 ± 2.33* 5.58 ± 0.43** 3.58 ± 0.41** 12  ± 1.13** 46.33 ± 3.95** 65% 
HD 500 mg/kg 
C .roseus 
10.25 ± 1.63 15.16 ± 1.60 8.58 ± 0.95** 6.41 ± 0.86** 10.83  ± 1.27** 51.25 ± 4.83** 61% 
 
Values are expressed as mean ± S.E.M., Values with different symbol are significantly differences.
*
P < 0.001 versus AOM control group                 
and 
**
P < 0.0001 versus AOM control group. 
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4.4.1 Macroscopical Findings 
The results are presented in (Figure 4.5) AOM-control rats developed grossly 
identifiable ACF in the colon. No aberrant crypts were identified with methylene blue in 
the intact colons of normal control rats. The number of ACF per colon, which is 
considered as a marker for tumour initiation, were significantly higher in the AOM-
control group compared to the C. roseus treated groups. At the same time the 
multiplicity of ACF (number of crypt per ACF), which is considered as a marker for 
tumour promotion, was significantly higher in AOM group. 
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Figure 4.5: Topographic views shows effect of C. roseus on ACF in methylene blue 
staining on rat colonic tissue; (A) Normal crypts from rats treated with 10% Tween 20, 
normal control; (B) AOM control group. (C) Reference group (5-Fluorouracil) + AOM 
(D) 250 mg/kg C. roseus + AOM; (E) 500 mg/kg C. roseus + AOM (10x). 
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4.4.2 Histopathology examination 
All the grossly visible colon lesions were evaluated histologically. Hematoxylin and 
Eosin stains in the AOM-control group contained comparatively more ACF, exhibiting 
marked nuclear nuclear atypia, with the crypts being longer and larger than normal. In 
higher magnification view the mildly dysplastic areas show elongation and slight 
stratification of nuclei. The epithelial cells in ACF have distinctive elongated nuclei, 
loss of cell polarity, increase in mitoses, lack of goblet cells and narrow lumen 
compared to the surrounding normal crypts (Figure 4.6). 
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Figure 4.6: Histological patterns of aberrant crypt foci. An effect of C. roseus on AOM-
induced ACF in rat’s colon; (A) Normal control group; (B) AOM control group; (C) 5-
Fluorouracil, Standard drug + AOM; (D) 250 mg/kg C. roseus + AOM; (E) 500 mg/kg 
C. roseus + AOM (H& E stain 100x). 
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4.5 Effects of C. roseus on biochemical parameters 
The total protein albumin was significantly increased in the treated C. roseus group 
compared to the AOM group. However, LDH and urea were decreased in treated groups 
compared to the AOM group. While there were no significant differences in gloucose, 
createnine, AST, ALT, ALP, and T. cholestrol in the C. roseus treated group compared to 
the AOM group. C. roseus treated groups showed restored levels of total protein, 
albumin, urea and LDH corresponding to normal values (Table 4.4, 4.5). 
Table 4.4: Effects of C. roseus on glucose, urea and createnine tests 
Animal  Group 
Glucose Urea Createnine 
(mmol/L) (mmol/L) µmol/L 
Normal 10.38 ± 0.56 5.44 ± 0.10 56.4 ± 5.52 
AOM 9 ± 0.51 7.13 ± 0.65
#
 40 ± 3.67 
5-flourouracil 7.2 ± 0.45 5.56 ± 0.25 46 ± 5.52 
LD C. roseus 7.7 ± 0.63 5.03 ± 0.29 
**
 42 ± 2.06 
HD C. roseus 7.52 ± 0.18 4.86 ± 0.24 
**
 43 ± 4.11 
All values expressed as mean ± SEM. Values with different symbol are significantly 
differences. 
#
P < 0.05 versus normal control group, 
*
P < 0.05 versus AOM control 
group,
**
P < 0.01 versus AOM control group 
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                Table 4.5: Effects of C. roseus on biochemical parameters 
 Animal  
Group 
T. protein 
 G/L) 
Albumin 
 (G/L) 
AST 
IU/L 
ALT 
IU/L 
ALP 
IU/L 
LDH 
U/L 
T.chol 
mmol/L 
 
Normal 64.37 ± 0.33 12.33 ± 0.21 203.2±18.48 60 ± 3.43 98.4 ± 3.02 1080.2 ± 24.88 1.3 ± 0.00 
AOM 58.20 ± 1.13
t
 11.00 ± 0.44
 t 
 181.83 ± 15.04 60.83 ± 5.36 86.66 ± 8.97 1414.33 ± 105.38
 t 
1.42 ± 0.11 
5-flourouracil 65.66 ± 1.54
**
 12.16 ± 0.16 164.83 ± 10.8 52.33 ± 3.43 133.16 ± 7.24 796.33 ± 55.18 
#
 1.35 ± 0.50 
LD C. roseus 64.83 ± 1.44
*
 12.33 ± 0.49* 164.66 ± 5.38 46 ± 4.31 120.66 ± 13.95 904.83 ± 77.85
 #
 1.43 ± 0.04 
HD C. roseus 64.40 ± 1.80
*
 12.7 ± 0.19
*
 206.6 ± 44.1 92.2 ± 35.84 131 ± 12.54 816.60 ± 73.61
 #
 1.96 ± 0.04 
All values expressed as mean ± SEM. Values with different symbol are significantly differences
 t
P< 0.05 versus normal control group, 
*
P< 
0.05 versus AOM control group, 
**
P< 0.01 versus AOM control group and 
#
P< 0.001 versus AOM control group. T. protein: Total protein, 
AST; Aspartate aminotransferase, ALT; Alanine Aminotransferase, ALP; Alkaline Phosphatase, LDH: Lactate dehydrogenase, and T. cho; 
Total cholesterol.
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4.6 Effects of C. roseus on hematological parameters 
The Hb, WBC, HCT, RBC, and Plt were significantly increased in the C. roseus treated 
group compared to the AOM group. While there were no significant differences in 
MCV, MCH, MCHC, RDW and WBC differential count in the C. roseus treated group 
compare to the AOM group. AOM induced oxidative damage in erythrocytes, leading to 
reduction of RBC counts and Hb, WBC, HCT, RBC and plt concentration. C. roseus 
treatment leads to an increase in concentration to reach normal values (Table 4.6, 4.7). 
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            Table 4.6: Effects of C. roseus on hematological parameters 
 Animal  
Group 
Hb 
G/L 
HCT 
(L/L) 
RBC 
(   12/L) 
MCV 
(fL) 
MCH 
(pg) 
MCHC 
(G/L) 
RDW 
(%) 
Normal 154.00 ± 1.12 0.464 ± 0.01 8.33 ± 0.13 55.8 ± 0.65 18.26 ± 0.20 328.4 ± 0.76 14.2 ± 0.46 
AOM  142.17 ± 2.35
t
 0.455 ± 0.01 8.195 ± 0.13 55.16 ± 0.96 17.55 ± 0.22 317.5 ± 2.46 14.76 ± 0.65 
5-flourouracil 154.83 ± 2.18
**
 0.488 ± 0.00
*
 8.435 ± 0.11 57.83 ± 0.79 18.36 ± 0.30 317.66 ± 2.72 15.08 ± 0.25 
LD C. roseus 162.33 ± 1.68
#
 0.498 ± 0.01
**
 8.861 ± 0.10
*
 56.66 ± 0.92 18.3 ± 0.14 325.16 ± 4.47 13.8 ± 0.20 
HD C. roseus 156.40 ± 3.21
**
 0.486 ± 0.01 8.522 ± 0.22 57.4 ± 0.66 18.38 ± 0.13 321 ± 1.59 15.72 ± 0.55 
All values expressed as mean ± SEM. Values with different symbol are significantly differences 
 t
P< 0.05 versus normal control 
group, 
*
P< 0.05 versus AOM control group 
**
P< 0.01 versus AOM control group and 
#
P< 0.001 versus AOM control group. Hb: 
Hemoglobin; HCT: Hematocrit RBC: Red blood cell, MCV: Mean Corpuscular Volume, MCH: Mean Corpuscular hemoglobin, 
MCHC: Mean Corpuscular hemoglobin Concentration, RDW: Red Cell Distribution. 
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 Table 4.7: Effects of C. roseus on hematological parameters 
Animal Group 
WBC Platelet Neutrophil Lymphocyte Monocyte 
Eosinophil 
% 
Basophil 
10
9
/L 10
9
/L % % % % 
Normal 12.98 ± 1.50 732.6 ± 26.33 18.36 ± 1.94 74.62 ± 2.45 3.96 ± 0.69 1.44 ± 0.43 0 ± 0.00 
AOM 8.08 ± 0.66
 t
 542.66 ± 94.38 17.93 ± 4.54 59.45 ± 12.37 5.35 ± 1.06 1.61 ± 0.54 0.1 ± 0.03 
5-flourouracil 7.28 ± 0.52 683 ± 35.33 28.46 ± 2.07 64.15 ± 3.21 5.86 ± 0.94 1.43 ± 1.19 0.08 ± 0.03 
LD C. roseus 12.35 ± 1.06
*
 924.66 ± 68.04
**
 29.75 ± 6.74 66.78 ± 6.97 3.2 ± 0.47 0.083 ± 0.07 0.016 ± 0.02 
HD C. roseus 10.10 ± 0.73 836.4 ± 48.97
*
 24.5 ± 2.04 72.42 ± 1.85 2.8 ± 0.65 0.94 ± 0.63 0.24 ± 0.16 
                    All values expressed as mean ± SEM. Values with different symbol are significantly differences.
 t
P < 0.05 versus normal 
control group, 
*
P< 0.05 versus AOM control group, WBC: white blood cell. 
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4.7 Effects of C. roseus on antioxidant and lipid peroxidation (TBRAS) in AOM 
induced ACF colonic aberrants 
Figure 4.7 shows the in vivo activities of oxidative enzymes involved in the colon 
antioxidant defense system. SOD enzyme level LD and HD were significantly increased 
in treatment groups compared with the AOM control group, whereas CAT enzyme HD 
levels were significantly increased in the treatment group compared to the AOM control 
group. In contrast, MDA values in colon rats were significantly decreased in the 
treatment groups when compared to the AOM control group. However, the 5- 
Flourouracil values were lower than those in the low dose and high dose groups. 
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Figure 4.7: Effect of C. roseus extract in vivo antioxidant activities parameters, in 
AOM -induced colon cancer rats. All values are expressed as the mean ± SEM. * = 
significantly different means compared to the AOM group, # = significantly different 
means compared to the normal group, p < 0.05. 
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4.8 Immunohistochemistry analysis 
Photomicrographs of ACF exhibiting grades of nuclear morphology from colons of rats 
receiving AOM were captured. All sections were cut parallel to the muscle layer. The 
presence of elongated and stratified nuclei were noted throughout the crypt. 
4.8.1 PCNA staining of colons and cell counting 
The PCNA was evaluated as a marker for cell proliferation in the colon specimens. 
Sections of colon samples from the control group and the C. roseus-treated group are 
shown (Figure 4.8). The PCNA positive staining cells in the nucleus (brown red) of 
mucosa of the colon tissue were much stronger in azoxymethane-treated rats than in the 
C. roseus-fed group. PCNA-negative cells (blue) were stained with hematoxylin. The 
PCNA labelling index is also shown in (Figure 4.9). The colon sections from the AOM 
control group showed a higher number of positive cells than those from the AOM + C. 
roseus-treated group. 
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Figure 4.8: Immunohistochemical staining: Effect of C. rosues on PCNA staining of 
colon mucosa; (A) Normal control group; (B) AOM-control group; (C) 5-Fluorouracil 
drug treated group + AOM; (D) 250 mg/kg C. roseus + AOM. (E) 500 mg/kg C. roseus 
+ AOM (IH staining 100x). 
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The PCNA-positive cells (%) of the colon tissue in the control group were 100%, 
whereas PCNA-positive cells (%) from the C. roseus-treated group were 41.8, 57.6 and 
67.5 % respectively. The two groups were significantly different at (P < 0.01) (Figure 
4.9).  
 
Figure 4.9: Effect of C. rosues on PCNA counting in AOM-induced ACF in rats. All 
values expressed as mean ± SEM. Values with symbol are significantly different versus 
control group, P < 0.01. 
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4.9 Gene expression profile 
4.9.1 Integrity of RNA 
The ratio of absorbance readings at 260nm and 280nm were used to indicate the quality 
of the RNA. The 260/280 ratio for our RNA preparation always ranged from 1.6-2.1 
(Table 4.8), which suggested good quality RNA. 
 The integrity of RNA was checked by agarose gel electrophoresis. Discrete 28S 
and 18S ribosomal RNA bands were obtained in each case, with the 28S band about 
twice the 18S band, indicating that the RNA extracted was intact and could be applied 
for RT-PCR. (Figure 4.10) shows a typical ethidium bromide stained-agarose RNA gel. 
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Table 4.8:  RNA concentration and purity measured by NanoDrop Spectrophotometer 
at 230, 260, 280, 320, 260/320 nm absorbance  
Sample ID 
Nucleic 
Acid 
Conc. 
Unit A260 A280 260/280 260/230 
Calibrator 1 1082.8 ng/µl 27.07 12.677 2.14 1.97 
Calibrator 2 634.6 ng/µl 15.865 7.546 2.1 2.04 
Calibrator 3 632.2 ng/µl 15.805 7.561 2.09 2.08 
Calibrator 4 464.1 ng/µl 11.603 5.549 2.09 1.45 
Calibrator 5 410.5 ng/µl 10.264 4.912 2.09 1.91 
Calibrator 6 502.5 ng/µl 12.561 6.076 2.07 2 
       
AOM1 271.4 ng/µl 6.785 3.259 2.08 1.94 
AOM2 320 ng/µl 8 3.806 2.1 0.84 
AOM3 569.3 ng/µl 14.233 6.771 2.1 1.76 
AOM4 1089 ng/µl 27.224 12.911 2.11 2.04 
AOM5 879.6 ng/µl 21.991 10.421 2.11 1.83 
AOM6 671 ng/µl 16.774 8.018 2.09 2.15 
       
C. roseus1 460.6 ng/µl 11.515 5.572 2.07 2.02 
C. roseus2 826.8 ng/µl 20.669 9.93 2.08 2.13 
C. roseus3 740 ng/µl 18.5 8.942 2.07 2.16 
C. roseus4 1014.9 ng/µl 25.374 12.064 2.1 2.1 
C. roseus5 905.1 ng/µl 22.628 10.902 2.08 2.11 
C. roseus6 829.3 ng/µl 20.733 9.872 2.1 2.1 
       
N: Normal control group, AOM: Azoxymethan treated group. 
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(A) 
 
(B) 
 
Figure 4.10: A typical ethidium bromide-stained agarose gel showing the integrity of 
the extracted RNA; (A) Visualized under Vilber Lourmat gel documentation system; 
(B) Visualized under UV light. 
28 S 
18 S 
28 S 
18 S 
AOM Normal C. roseus 
AOM Normal C. roseus 
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4.10 C. roseus activates apoptosis cell death 
4.10.1 Effect of C. roseus on apoptosis gene expression 
The gene expression levels of the target genes in animal colon tissue samples were 
normalized using both HPRT-1 and Tbp endogenous reference genes. The expression 
levels of Bax, Bcl2, p53 and the two endogenous reference genes were subsequently 
validated by RT-PCR measurements. According to a standard curve (appendix A9) all 
genes showed that efficiency was between 90-110 % and the slope between (-3.1) and (-
3.5), which is within the reference criteria necessary to run the quantitative RT-PCR 
(Table 4.9). After data analysis of Ct values by Gene EX software and normalized to the 
reference genes HPRT-1 and Tbp, all measured mRNAs showed different expressions 
between calibrator group (normal control tissue), AOM group (cancer group) and C. 
roseus treatment rats group. The expression of Bax and Bcl2 genes in AOM group were 
significantly decreased, being (1.197 ± 0.003), P < 0.003, (0.24 ± 0.20) P < 0.003 
respectively, with the fold being lower when compared with the normal rat group 
(Calibrator group). However, the difference was insignificant for the p53 gene (0.76 ± 
0.23) P < 0.23 in terms of the fold being lower when compared with normal rats.  
 C. roseus induced the expression of apoptosis-related genes that caused 
significant up-regulation of pro-apoptotic protein Bax (1.24 ± 0.34), P < 0.01 and p53 
1.30 ± 0.01, P < 0.01. Although C. roseus treatment did not significantly modify the 
expressed levels of anti-apoptotic protein Bcl-2 (0.28 ± 0.13), P < 0.003 in the mucosa 
compared of the AOM –injection rats. Bcl2 gene expression did not change with C. 
roseus treatment in contrast to Bax and p53 transcript, which was significantly up-
regulated. In addition C. roseus treatment caused a switch in the Bcl-2/Bax ratio, which 
was elevated in the mucosa of AOM-injected rats (Bcl-2/Bax>1), and was reversed after 
C. roseus treatment (Bcl-2/Bax <1) as shown in (Figure 4.11 and Table 4.10). 
 115 
 
 
Figure 4.  : Changes in the mRNA expression levels of p53, Bcl-2 and Bax in the 
colonic mucosa of AOM-injected rats and C. roseus treated AOM-injected rats. Real-
time PCR was done in triplicate. The mRNA level from colonic mucosa of normal 
control rats was used as an external reference. The levels of Hprt1 and Tbp mRNA were 
used as an internal reference to normalize the data. Data are presented as the mean ± 
SEM, P < 0.05. 
Table 4.9: Measured efficiency slope and R
2
 of target and endogenous reference genes 
using the Ct slope method with 5 concentrations points 
Genes Hprt1 Tbp Act-b P53 Bax Bcl2 
Reference 
criteria 
Efficiency 109.4  108.4 96.0   110 109.4  108.9 90-110 
Slope  -3.1  -3.1  -3.4  -3.1 -3.1  -3.1 (-3.1) - (-3.5) 
y-inter  30.3  23.3  32.1  33.4  30.3  30.2 -- 
R
2
  0.99  0.99  0.98  0.99  0.99  0.98 
Not less than 
0.98 
 
* 
* 
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Table 4.10: Effect of AOM, C. roseus extract intake on mRNA gene expression levels 
in AOM-induced rat colon tissue 
Group Bax Bcl2 p53 
Calibrator 1 1 1 
AOM 1.197 ± 0.003*  0.24 ± 0.200*  0.76 ± 0.23 
C. roseus 1.24 ± 0.34*  0.28 ± 0.13 1.30 ± 0.01* 
All values are expressed as mean fold changes of mRNA from 6 rats ± S.E.M. 
Statistical analysis of differences was performed by a two-tailed unpaired student’s t 
test. Means with different superscripts are significantly different. P < 0.05  
4.11 In vitro chemo-protective activity of C. roseus crude extracts and isolated 
fractions  
The inhibitory effect of the crude extract and fractions of C. roseus  has been tested in 
vitro against the human colon cancer HT-29 cell line and normal human colon cells 
CCD841 using MTT assay. The crude extract inhibited colon cancer cells showing 
maximum inhibition on HT-29 cells (13.84 %) at the concentration 166.66μg/ml, with 
no variations in the cell viability of CCD841 cells having been observed. At the same 
time the fractions of the crude extract of C. roseus were also tested for their 
antiproliferative effect on both HT-29 and CDD841 cell lines. Amongst the 8 fractions 
tested, fraction 5 (F5) showed maximum inhibition on HT-29 cells (86.27 %) at the 
concentration 166.66μg/ml. F4 and F7 also showed strong inhibition activities against 
HT-29 cells of 57.83% and 62.53 % respectively. The remaining fractions showed 
moderate inhibition activities. On the other hand, there were almost no variations in the 
cell viability of CCD841 cells observed. While the increase in the percentage of 
inhibition was seen with F4, F5 and F7 of C. roseus, which also showed no cytotoxicity 
against normal colon cells (Figure.4.12 and Figure 4.13), photomicrographs showed the 
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effects of C. roseus fractions treatment on CCD841 and the HT-29 cells in comparison to 
the untreated cells. 
 
Figure.4.12: The effect of the crude extract of C. roseus and its fractions on the growth 
of human HT-29 cell line. Cells were seeded in 96-well plate and treated with different 
concentrations of both C. roseus crude extract and fractions (166.66 µg/ml) for 48h. The 
inhibition of HT-29 growth was assessed by MTT assay. The results represent the mean 
of triplicate measurement.  
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Figure 4.13: Photomicrographs of HT29 and CCD841 cells showing the effects C. 
roseus fractions treatment; (A) CCD841 cells without treatment; (B) cells treated with 
166.66µg/ml F5; (C) HT29 cells without treatment; (D) HT29 cells treated with 
166.66µg/ml F5 (magnification 10x). 
4.11.1 Identification of active constituents of the active fractions  
We applied UPLC-PDA and LC-MS using positive and negative ionization mode in 
order to know the chemical structural information and to identify the alkaloid or 
phenolic constituents and other active compounds of C. roseus Approximately three 
compounds were detected in F5 from them were characterized on the basis of the UV 
spectra and MS fragmentation patterns in comparison with literature or by searching the 
dictionary of natural products on DVD, Version 20:2 (2011) (CRC Press, Taylor & 
A B 
C D 
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Francis Group, London, UK). In addition three active compounds were detected in C. 
roseus F5 and three of them were identified Typical HPLC-TOF/MS peaks and UV 
diode array chromatograms of the C. roseus F5 fractions are shown in (Figure 
4.14).Tables 4.11 showed the identification of all the peaks detected with their retention 
time, UV max, observed m/z and the m/z of fragment ions. The C. roseus F5 compounds 
include ajmalicine at m/z 351.1722 (Figure 4.15), vindoline at m/z 457.2222 (Figure 
4.16) and vindolidine at m/z 427.2140 (Figure 4.17)  
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Table 4.11: Identification of alkaloid compounds in C. roseus F3 by UPLC-PDA and LC-MS data using positive 
ionization mode 
Sample 
Rt 
time(min) 
m/z of fragment ions 
observed 
Suggested 
formula 
 
Observed 
m/z 
Tentative 
identification 
M.W. (g/mol) 
C. roseus F5 
1.188 280, 350, 191, 300, 254 C26H22O 351.1722 Ajmalicine 350.17 
23231 280, 350, 191, 300, 254 C21H32N2O9 457.2222 Vindoline 456.22 
2.411 280, 350, 191, 300, 254 C25H30O6 427.214 Vindolidine 426.21 
  RT: Retention Time, M.W.: Mol 
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Figure 4.14: HPLC-TOF/MS and UV diode array chromatograms of C. roseus fraction 5 (F5); (A) Diode 
array detection UV spectra at 351 nm; (B) TOF MS peaks in positive mode ionization 
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1 
3 2 
1 
 112 
 
 
Figure 4.15: Mass Spectrum (TOF MS ES+), chemical structure and UV max spectra of ajmalicine (peak No. 1) 
identified in C. roseus F5. 
 
 
Ajmalicine (M.W.:352.43 g/mol) 
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Figure 4.16: Mass Spectrum (TOF MS ES+), chemical structure and UV max spectra of vindoline (peak No. 2) 
identified in C. roseus F5. 
 
 
 
Vindoline (M.W.:456.53 g/mol) 
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Figure 4.17: Mass Spectrum (TOF MS ES+), chemical structure and UV max spectra of vindolidine (peak No. 4) 
identified C. roseus F5. 
 
Vindolidine   
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4.12 Antioxidant activity of A. ilicifolius extract in vitro 
4.12.1 Ferric-reducing antioxidant power (FRAP) assay results  
Figure 4.18 shows that A. ilicifolius had a strong reducing power as it attained 
significantly p<0.05 with  higher FRAP value 1670 ± 0.277 µmol Fe
 
II/g as compared to 
BHT and Ascorbic acid 521.4 ± 0.82 and 1181.9 ± 0.274µmol Fe
 
II/g respectively. 
Furthermore, the FRAP value for the synthetic reference antioxidants qurcetin and gallic 
acid were reported to be 2267.1 ± 0.55 and 2640 ± 0.277 µmol Fe II/g respectively with 
regression coefficient of (standard curve equation: y = 0.0006x + 0.0013, R
2
 = 1) as 
shown in appendix A1. 
 
Figure 4.18: Ferric reducing activity of A. ilicifolius extract. All values are expressed as 
mean ± SEM. Mean with different letters indicate significantly different values P< 0.05. 
BHT; Butylatedhydroxyl toluene  
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4.12.2 DPPH free radical scavenging activity of A. ilicifolius extract in vitro 
Antioxidant activity is measured as the capacity of the tested compound to reduce the 
stable DPPH radical. The scavenging capability of A. ilicifolius increases with the 
increase in concentration of the A. ilicifolius and is same as the BHT. Figure 4.19 The 
IC50 value represents the concentration needed to cause 50 % inhibition of DPPH 
Different concentrations of the extracts, as well as BHT, quercetin and trolox, were used 
and the IC50 values were determined to be 12.20 µg/ml for A. iIlicifolius 17.40 µg/ml for 
BHT, 7.40 µg/ml for quercetin and 6.20 µg/ml for trolox with standard curve equation: 
y = 1.2997x + 0.1834, R
2
 = 0.997) as shown in Appendix A2. 
 
Figure 4.19: Scavenging Activity of A. ilicifolius extract (DPPH). All values are 
expressed as mean ± SEM, P< 0.05. 
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4.12.3 Total phenolic and flavonoids content assay  
Total phenolic content of the ethanolic extract of A. ilicifolius was determined to 281.90 
± 0.27 mg (Gallic acid equivalents) per g of extracts with  standard curve equation: y = 
0.0007x + 0.0015, R
2
 = 0.989 as shown in Appendix A3.  
           The total Flavonoids were 46.79 ± 0.005 mg (Quercetin equivalents) per g of 
extracts (standard curve equation: y = 0.0054x + 0.005, R
2
= 0.999) as shown in 
appendix A4 with ratio flavonoids/phenolic of 0.2. Thus, phenolic compounds were the 
predominant antioxidant components in A. ilicifolius extracts, which leads to more 
potent radical scavenging effect.  
4.13 Acute toxicity study  
Acute toxicity study is an experimental study in which selected rats are treated with the 
A. ilicifolius extract at a dose of 2 g/kg and 5 g/kg and were kept under observation for 
14 days. All the animals remained alive and did not manifest any significant visible of 
toxicity at these doses. By chemical and histologic indicators, no hepatic or renal 
toxicity was seen. The finding from the applications of the A. ilicifolius extract to the 
control rats provided sufficient evidence to conclude that the orally administered extract 
was safe and presented no extract-related toxicity even at the highest dose of 5 g/kg as 
shown in (Table 4.12, 4.13 and Figure 4.20). 
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Table 4.12: Effects of A. ilicifolius extract on kidney biochemical parameters in acute toxicity 
Dose 
Sodium 
(mmol/L) 
Pottasium(
mmol/L) 
Chloride 
(mmol/L) 
CO2 
(mmol/L) 
Anion gap 
(mmol/L) 
Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
Vehicle (10% 
Tween-20) 
0.49 +138.68  0.19 +5.25  1.95 +104.43  0.88 +22.55  0.97 +18.25  0.38 +5.86  1.51 +51.05  
LD A. ilicifolius 
(2g/kg) 
0.52 +138.35  0.18 +5.33  1.52 +103.07  0.79 +23.61  1.12 +17.13  0.41 +5.76  1.28 +48.94  
HD A. ilicifolius 
(5g/kg) 
0.58 +137.42  0.17 +5.09  1.21 +101.95  0.95 +23.38  0.91 +17.41  0.45 +6.02  1.73 +49.36  
 
Values expressed as mean ± SEM. There are no significant differences between groups, P < 0.05. 
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Table 4.13: Effects of A. ilicifolius extract on liver biochemical parameters in acute toxicity. 
Dose 
T. protein 
(g/L) 
Albumin 
(g/L) 
Globulin 
(g/L) 
TB 
(µmol/L) 
CB 
(µmol/L) 
AP 
 (IU/L) 
ALT 
 (IU/L) 
AST 
(IU/L) 
GGT 
(IU/L) 
Vehicle (10% 
Tween-20) 1.62 +72.29  0.65 +11.47  1.69 +59.76  0.19 +1.94  0.00 +1.00  9.03 +132.58  3.68 +52.35  8.55 +1513.45  0.91 +4.96  
LD A. ilicifolius 
(2 g/kg) 1.23 +71.68  0.49 +11.31  1.73 +58.81  0.17 +2.06  0.00 +1.00  8.27 +133.45  2.13 +52.47  6.59 +154.26  1.13 +5.02  
HD A. ilicifolius 
(5 g/kg) 1.08 +71.83  0.41 +10.84  1.88 +60.13  0.20 +1.87  0.00 +1.00  8.62 +134.15  3.28 +53.24  5.91 +158.02  1.02 +5.28  
Values expressed as mean ± SEM There are no significant differences between groups, P< 0.05. Tb: Total bilirubin; Cb: Conjugated 
bilirubin; Alp: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: G-Glutamyl Transferase.
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Figure 4.20: Histological sections. Effect of A. ilicifolius on liver and kidney on acute 
toxicity test (H & E stain; 20x). 
Vehicle(Tween 2 ) Liver  
LD A. ilicifolius Liver 
HD. A. ilicifolius Liver 
Vehicle(Tween 2 ) Kidney  
LD A. ilicifolius Kidney 
HD. A. ilicifolius Kidney 
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4.14 Analysis of body weight 
The body weight of all rats were taken at the beginning (1 week) of the experiment then 
weekly up to 10 weeks (Figure 4.21). Although there is differences between groups, 
statistically there were no significant differences in the body weight among the groups. 
 
Figure 4.21: Effect of A. ilicifolius on body weight of rat’s in different experimental 
groups. All values expressed as mean ± SEM. There were significant changes in body 
weights were observed in all rat’s group, P< 0.05. 
4.15 Effect of A. ilicifolius on colonic ACF 
ACF were predominantly observed in the middle colon. ACF present in the colon were 
counted and the average of total number of ACF as well as the number of crypts per 
focus was obtained. ACF were observed in the colon as well as multicrypt clusters 
(more than four crypts/focus) of aberrant crypts (Table 4.14) Rats treated with AOM 
and fed with the A. ilicifolius extract showed a significant lower number of total 
ACF/colon compared with the AOM-control rats (65 % and 53 % respectively 
inhibition, P< 0.0001). The incidence of multiple aberrant crypts/focus was also 
significantly inhibited in rats fed with A. ilicifolius as compared with the AOM-control 
rats.
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Table 4.14: Effect of A. ilicifolius on AOM-induced colonic ACF containing four or more aberrant crypts in rats 
Groups 1 crypt 2 crypts 3 crypts 4 crypts 
5&more 
crypts 
Total ACF 
inhibition 
% 
AOM control 19.50 ± 3.62 29.79 ± 4.89 23.04 ± 2.70 24.67 ± 2.22 34.33 ± 4.94 131.33 ± 15.09 0 
5-Fluorouracil 10.16 ± 1.04 9.50 ± 2.04* 7.91 ± 0.69** 6.25 ± 0.81** 7 ± 0.64** 40.83 ± 3.06** 69% 
LD 250 mg/kg 
A. ilicifolius 
18.36 ± 3.14 10.05 ± 1.63* 4.30 ±.0.16** 4.47 ±.0.57** 8.13 ± 0.89** 45.33 ± 4.43** 65% 
HD 500 mg/kg 
A. ilicifolius 
17.08 ± 2.37 13.08 ± 2.55 11.91 ±.0.95** 8.75 ±.0.86** 9.08 ± 1.55** 62 ± 3.72** 53% 
Values are expressed as mean ± S.E.M., Values with different symbol are significantly differences.
*
P< 0.001 versus AOM control group 
and 
**
P< 0.0001 versus AOM control group.  
 123 
 
 
4.16 Macroscopical Findings 
The results are presented in (Figure 4.22) AOM-control rats developed grossly 
identifiable ACF in the colon. No aberrant crypts were identified with methylene blue in 
the intact colons of normal control rats. The number of ACF per colon, which is 
considered as a marker for tumour initiation were significantly higher in the AOM-
control group compared to the A. ilicifolius treated groups. The multiplicity of ACF 
(number of crypt per ACF), which is considered as a marker for tumour promotion, was 
significantly higher in AOM group. 
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Figure 4.22: Topographic views show effect of A. ilicifolius on ACF in methylene blue 
staining on rat colonic tissue; (A) Normal crypts from rats treated with 10% Tween 20, 
normal control; (B) AOM control group; (C) Reference group (5-Fluorouracil) + AOM 
(D) 250 mg/kg A. ilicifolius + AOM; (E) 500 mg/kg A. ilicifolius + AOM (10x). 
B A 
C D 
E 
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4.17 Histopathology examination 
All the grossly visible colon lesions were evaluated histologically (Haematoxylin and 
Eosin stains). Normal control group showed circular shape and basal location of the 
nuclei. AOM control group contain comparatively more ACF exhibiting marked nuclear 
atypia, significantly decreased goblet cells, narrow lumen, ACF are longer and larger 
than normal, intense staining appearance of cell’s cytoplasm. The epithelial cells in 
ACF have distinctive elongated and stratified nuclei, loss of cell polarity, and increase 
in mitoses compared to the surrounding regular crypts (Figure 4.23). Plant extract 
treated groups showed increases the apoptosis, reduced mitosis and cellular 
proliferation, and reduced the induction of ACF in rat colon with mild morphological 
changes of ACF compared with AOM-treated group (cancer control). 
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Figure4.23: Histological patterns of aberrant crypt foci. Effect of A. ilicifolius on 
AOM-induced ACF in rat’s colon; (A) Normal control group; (B) AOM control group; 
(C) Standard drug group, 5-Fluorouracil + AOM; (D) 250 mg/kg A. ilicifolius + AOM; 
(E) 500 mg/kg A. ilicifolius + AOM (H& E stain 100x). 
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4.18 Effects of A. ilicifolius on biochemical parameters 
The Total protein, and Albumin significantly increased in treated A. ilicifolius group 
compared to the AOM However, urea was significantly decreased in the treated A. 
ilicifolius groups compared to the AOM group, While there were no significant 
differences in glucose, createnine, AST, ALT, ALP, LDH and T. cholesterol in the A. 
ilicifolius treated group compare to the AOM group. A. ilicifolius treated group restored 
the level of T. protein, Alb and urea to reach normal values (Table 4.15, 4.16). 
Table 4.15: Effects of A. ilicifolius on glucose, urea and createnine 
Animal  Group 
Glucose Urea Createnine 
(mmol/L) (mmol/L) µmol/L 
Normal 10.38 ± 0.56 5.44 ± 0.10 56.4 ± 5.52 
AOM 9 ± 0.51 7.13 ± 0.65
t
 40 ± 3.67 
5-flourouracil 7.2 ± 0.45 5.56 ± 0.25
*
 46 ± 5.52 
LD A. ilicifolius 8.51 ± 0.26 4.76 ± 0.20
*
 39 ± 4.48 
HD A. ilicifollius 7.66 ± 0.32 5.31 ± 0.19
*
 38.6 ± 3.12 
All values expressed as mean ± SEM.
 t
P< 0.05 versus normal control group, *P< 0.01 
versus AOM control group.  
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Table 4.16: Effects of A. ilicifolius on biochemical parameters 
 Animal  Group 
T. protein 
 G/L) 
Albumin 
 (G/L) 
AST 
IU/L 
ALT 
IU/L 
ALP 
IU/L 
LDH 
U/L 
T. chol 
mmol/L 
 
Normal 64.37 ± 0.33 12.33 ± 0.21 203.2± 18.48 60 ± 3.43 98.4 ± 3.02 1080.2 ± 24.88 1.3 ± 0.00 
AOM 58.20 ± 1.13
t
 11.00 ± 0.44 181.83± 15.04 60.83 ± 5.36 86.66 ± 8.97 1414.33 ± 105.38 1.42 ± 0.11 
5-flourouracil 65.66 ± 1.54
**
 12.16 ± 0.16 164.83± 10.8 52.33 ± 3.43 133.16 ± 7.24 796.33 ± 55.18 
#
 1.35 ± 0.50 
LD A. ilicifolius 61.5 ± 0.84 13.16 ± 0.16
#
 157.5± 5.22 44.33 ± 4.08 107.5 ± 8.17 1218.1 ± 140.08 1.38 ± 0.03 
HD A. ilicifollius 63.2 ± 0.97
*
 13.4 ± 0.41
#
 168.8 ± 9.54 39.6 ± 0.99 111.6 ± 6.14 1233.4 ± 156.45 1.4 ± 0.04 
All values expressed as mean ± SEM. Values with different symbol are significantly differences. 
 t
P < 0.05 versus normal control group, 
*
P< 0.05 versus AOM control group,
**
P< 0.01 versus AOM control group and 
#
P< 0.001 versus AOM control group. T. protein: Total 
protein, AST; Aspartate aminotransferase, ALT; Alanine Aminotransferase, ALP; Alkaline Phosphatase, LDH: Lactate dehydrogenase, and 
T. cho; Total cholesterol 
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4.18.1 Effects of A. ilicifolius on hematologic parameters 
The Hb and Plt were significantly increased in the treated A. ilicifolius group compared 
to the AOM group, while there were no significant differences in HCT, RBC, MCV, 
MCH, MCHC, RDW and total WBC count in  the A. ilicifolius treated group compared 
to the AOM group. AOM induced oxidative damages in erythrocytes, leading to 
reduction Hb and plt concentration. A. ilicifolius treatment leads to increase the 
concentration to reach normal values. (Table 4.17, 4.18) 
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Table 4.17: Effects of A .ilicifolius on hematological parameters 
 Animal  Group 
Hb 
G/L 
HCT 
(L/L) 
RBC 
(10 12/L) 
MCV 
(fL) 
MCH 
(pg) 
MCHC 
(G/L) 
RDW 
(%) 
Normal 154.00 ± 1.12 0.464 ± 0.01 8.33 ± 0.13 55.8 ± 0.65 18.26 ± 0.20 328.4 ± 0.76 14.2 ± 0.46 
AOM  142.17 ± 2.35
 t
 0.455 ± 0.01 8.195 ± 0.13 55.16 ± 0.96 17.55 ± 0.22 317.5 ± 2.46 14.76 ± 0.65 
5-flourouracil 154.83 ± 2.18
**
 0.488 ± 0.00 8.435 ± 0.11 57.83 ± 0.79 18.36 ± 0.30 317.66 ± 2.72 15.08 ± 0.25 
LD A. ilicifolius 151 ± 1.15* 0.45 ± 0.01 8.29 ± 0.08 55 ± 0.73 18.2 ± 0.17 330 ± 5.24 14.26 ± 0.48 
HD A ilicifollius 153 ± 1.57** 0.46 ± 0.01 8.46 ± 0.06 55 ± 0.73 18.08 ± 0.18 328.2 ± 3.03 14.78 ± 0.33 
All values expressed as mean ± SEM. Values with different symbol are significantly differences.
 t
P < 0.05 versus normal control 
group, 
*
P< 0.05 versus AOM control group,
**
P< 0.01 versus AOM control Hb: Hemoglobin; HCT: Hematocrit RBC: Red blood cell,  
MCV: Mean Corpuscular Volume, MCH: Mean Corpuscular hemoglobin, MCHC: Mean Corpuscular hemoglobin Concentration, 
RDW: Red Cell Distribution. 
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Table 4.18: Effects of A. ilicifolius on hematological parameters 
Animal  Group 
WBC 
10
9
/L 
Platelet 
10
9
/L 
Neutrophil 
% 
Lymphocyte 
% 
Monocyte 
% 
Eosinophil 
% 
Basophil 
% 
Normal 12.98 ± 1.50 732.6±26.33 18.36±1.94 74.62±2.45 3.96±0.69 1.44±0.43 0±0.00 
AOM 8.08 ± 0.66
 t
 542.66±94.38 17.93±4.54 59.45±12.37 5.35±1.06 1.61±0.54 0.1±0.03 
5-flourouracil 7.28 ± 0.52 683±35.33 28.46±2.07 64.15±3.21 5.86±0.94 1.43±1.19 0.08±0.03 
LD A. ilicifolius 8.76 ±1.15 771±29.04 22.8±2.51 70.6±2.98 5.56±1.17 0.86±0.19 0.05±0.02 
HD A. ilicifollius 11.1 ± 0.54 834±53.49
**
 25.66±2.59 69.04±2.93 4.72±0.48 0.46±0.13 0.06±0.02 
All values expressed as mean ± SEM. Values with different symbol are significantly differences,
 t
P < 0.05 versus normal control 
group, 
*
P< 0.05 versus AOM control group, and
**
P< 0.01 versus AOM control WBC: white blood cell. 
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4.19 Effects of A. ilicifolius on antioxidant and lipid peroxidation (TBRAS) in 
AOM induced ACF colonic aberrant 
Figure 4.24 shows the in vivo activities of oxidative enzymes involved in the colon 
antioxidant defense system. SOD and CAT enzyme levels were decreased in the AOM 
groups when compared with the normal control group and similarly their levels were 
lower in the high dose plant group when compared with the low dose group. 
Furthermore, MDA values in colon of the low dose group rats were lower than those in 
the high dose groups However, the 5- Fluorouracil values was lower than those in the 
low dose and high dose groups. 
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Figure 4.24 Effect ofA.ilicifolius extracts in vivo antioxidant activities parameters, in 
AOM -induced colon cancer rats. All values are expressed as the mean ± SEM. * = 
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significantly different means compared to the AOM group, # = significantly different 
means compared to the normal group, p < 0.05. 
4.20 ImmunohistochemistryAnalysis 
Photomicrographs of ACF exhibiting grades of nuclear morphology from colons of rats 
receiving AOM were captured. All sections were cut parallel to the muscle layer. Note 
the presence of elongated and stratified nuclei were noted throughout the crypt. 
4.20.1 PCNA staining of colons and cell counting 
The PCNA was evaluated as a marker for cell proliferation in the colon specimens. 
Sections of colon samples from the control group and the or A.ilicifolius-treated group 
are shown (Figure 4.25). The PCNA positive staining cells in the nucleus (brown red) of 
mucosa of the colon tissue were much stronger in azoxymethane-treated rats than in the 
C. roseus-fed group. PCNA-negative cells (blue) were stained with hematoxylin.  
             The PCNA labelling index is also shown in (Figure 4.26). The colon sections 
from the AOM control group showed a higher number of positive cells than those from 
the AOM + A. ilicifolius -treated group 
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Figure 4.25: Immunohistochemical staining: Effect of A. ilicifolius on PCNA staining 
of colon mucosa in AOM-induced ACF in rats. (A) Normal control group. (B) AOM-
control group. (C) 5-Fluorouracil drug treated group + AOM. (D) 250 mg/kg A. 
ilicifolius + AOM; (E) 500 mg/kg A. ilicifolius + AOM (PCNA staining 100x). 
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                    The percentage of PCNA-positive cells of the colon tissue in the AOM 
control group were 100 %, whereas the percentage of PCNA-positive cells from the 5- 
Fluorouracil and A. ilicifolius -low and high dose treated group were 25.47, 35.47 and 
47.30 % (Figure 4.31). 
 
 
Figure 4.26: Effects of A. ilicifolius on PCNA counting in AOM-induced ACF in rats. 
All values are expressed as the mean ± SEM. * = significantly different means 
compared to the AOM group, # = significantly different means compared to the normal 
group, P< 0.01. 
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4.21 Gene expression profile 
4.21.1 Integrity of RNA 
The ratio of absorbance reading at 260 nm and 280 nm were used to indicate the quality 
of the RNA .The 260/280 ratio for our RNA preparation always ranged from 1.6-2.1 
(Table4.19), which suggested good quality RNA. 
The integrity of RNA was checked by agarose gel electrophoresis. Discrete 28S and 
18S ribosomal RNA bands were obtained in each case, with the 28S band about twice 
the 18S band, indicating that the RNA extracted was intact and could be applied for RT-
PCR (Figure 4.27) shows a typical ethidium bromide stained-agarose RNA gel. 
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Table 4.19: RNA concentration and purity measured by NanoDrop Spectrophotometer 
at 230, 260, 280, 320, 260/320 nm absorbance  
Sample ID 
Nucleic 
Acid 
Conc. 
Unit A260 A280 260/280 260/230 
Calibrator 1 1082.8 ng/µl 27.07 12.677 2.14 1.97 
Calibrator 2 634.6 ng/µl 15.865 7.546 2.1 2.04 
Calibrator 3 632.2 ng/µl 15.805 7.561 2.09 2.08 
Calibrator 4 464.1 ng/µl 11.603 5.549 2.09 1.45 
Calibrator 5 410.5 ng/µl 10.264 4.912 2.09 1.91 
Calibrator 6 502.5 ng/µl 12.561 6.076 2.07 2 
       
AOM1 271.4 ng/µl 6.785 3.259 2.08 1.94 
AOM2 320 ng/µl 8 3.806 2.1 0.84 
AOM3 569.3 ng/µl 14.233 6.771 2.1 1.76 
AOM4 1089 ng/µl 27.224 12.911 2.11 2.04 
AOM5 879.6 ng/µl 21.991 10.421 2.11 1.83 
AOM6 671 ng/µl 16.774 8.018 2.09 2.15 
       
A. ilicifolius1 690.9 ng/µl 17.273 8.136 2.12 2.15 
A. ilicifolius2 1144.1 ng/µl 28.603 13.362 2.14 2.17 
A. ilicifolius3 1007.2 ng/µl 25.18 11.782 2.14 1.84 
A. ilicifolius4 1317.7 ng/µl 32.943 15.552 2.12 2.16 
A. ilicifolius5 1024.2 ng/µl 25.605 12.17 2.1 2.21 
A. ilicifolius6 617.5 ng/µl 15.438 7.625 2.02 1.9 
       
N: Normal control group, AOM: Azoxymethan treated group. 
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(A) 
 
(B) 
 
Figure 4.27: A typical ethidium bromide-stained agarose gel showing the integrity of 
the extracted RNA; (A) Visualized under Vilber Lourmat gel documentation system; 
(B) Visualized under UV light. 
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4.21.2 A. ilicifolius activates apoptosis cell death 
4.21.2.1 Effect of A. ilicifolius on apoptosis gene expression 
The gene expression levels of the target genes in animal colon tissue samples were 
normalized using both HPRT-1 and Tbp endogenous reference genes. The expression 
levels of Bax, Bcl2, p53 and the two endogenous reference genes were subsequently 
validated by RT-PCR measurements. According to a standard curve (Appendix A9) all 
genes showed efficiency was between 90-110 % and the slope between (-3.1) and (-3.5) 
which is within the reference criteria  necessary to run the quantitative RT-PCR (Table 
4.20). After data analysis of Ct values by Gene EX software and normalized to the 
reference genes HPRT-1 and Tbp, all measured mRNAs showed different expression 
between calibrator group (normal control tissue), AOM group (cancer group) and A. 
ilicifolius treatment rats group. The expression of Bax and Bcl2 genes in AOM group 
were significantly decreased, being (1.197 ± 0.003), P < 0.003, (0.24 ± 0.20) P < 0.003 
respectively, with the fold being lower when compared with the normal rats group 
(Calibrator group). However, the difference was non-significant for p53 gene (0.76 ± 
0.23) P < 0.23 fold lower compared with normal rats Table 4.21. 
A. ilicifolius induced the expression of apoptosis-related genes that caused significantly 
up-regulation of pro-apoptotic protein Bax (0.92 ± 0.26), P < 0.024 and p53 1.54 ± 0.28, 
P < 0.02 while A .ilicifolius treatment did not significantly modify the expression level 
of anti-apoptotic protein Bcl-2 (0.656 ± 0.18), P < 0.057 in the mucosa compared of the 
AOM –injection rats. Bcl2 gene expression did not significantly change with A. 
ilicifolius treatment in contrast to Bax and p53 transcript which was significantly up-
regulated. In addition A. ilicifolius treatment caused a switch in the Bcl-2/Bax ratio, 
which was elevated in the mucosa of AOM-injected rats (Bcl-2/Bax>1) and was 
reversed after A. ilicifolius treatment (Bcl-2/Bax <1), (Figure 4.28 and Table 4.21). 
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Figure 4.28: Changes in the mRNA expression levels of Bax, Bcl-2 and P53 in the 
colonic mucosa of AOM-injected rats and A. illicifolius treated AOM-injected rats. 
Real-time PCR was done in triplicate. The mRNA level from colonic mucosa of normal 
control rats was used as an external reference. The level of Hprt1 and Tbp mRNA were 
used as an internal reference to normalize the data. Data are presented as the mean ± 
SEM, P < 0.05. 
Table 4.20: Measured efficiency slope and R
2
 of target and endogenous reference genes 
using the Ct slope method with 5 concentrations points 
Genes Hprt1 Tbp Act-b p53 Bax Bcl2 
Reference 
criteria 
Efficiency 109.4  108.4 96.0   110 109.4  108.9 90-110 
Slope  -3.1  -3.1  -3.4  -3.1 -3.1  -3.1 
(-3.1)- (-
3.5) 
y-inter  30.3  23.3  32.1  33.4  30.3  30.2 -- 
R
2
  0.99  0.99  0.98  0.99  0.99  0.98 
Not less 
than 0.98 
 
 
 
* 
* 
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Table 4.21: Effect of AOM, A. ilicifolius extract intake on mRNA gene expression 
levels in AOM-induced rat colon tissue 
Group Bax Bcl2 p53 
Calibrator 1 1 1 
AOM 0.197 ± 0.003*  0.24 ± 0.20*  0.76 ± 0.23 
A. illicifolius 0.92 ± 0.26*   0.65 ± 0.18 1.54 ± 0.28* 
All values are expressed as mean fold changes of mRNA from 6 rats ± S.E.M. 
Statistical analysis of differences was performed by a two-tailed unpaired student’s t 
test. Means with different superscripts are significantly different, P < 0.05. 
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4.22 In vitro chemo-protective activity of A. ilicifolius crude extracts and isolated 
fractions  
The inhibitory effect of the crude extract and fractions of A. ilicifolius has been tested in 
vitro against human colon cancer HT-29 cell line and normal human colon cells CCD841 
using MTT assay. The crude extract inhibited colon cancer cells showed maximum 
inhibition on HT-29 cells (13.77 %) at the concentration 166.66 μg/ml and no variations 
in the cell viability of CCD841 cells observed, at the same time the fractions of the crude 
extract of A. ilicifolius were also tested for their antiproliferative effect on both HT-29 
and CDD841 cell lines. Amongst the 2 fractions tested, fraction 3 (F3) showed maximum 
inhibition on HT-29 cells (51.29 %) at the concentration 166.66 μg/ml also showed no 
cytotoxicity against normal colon cells (Figure.4.29 and Figure 4.30) Photomicrographs 
showing the effects A. ilicifolius fractions treatment on CCD841 and (HT-29) cell in 
comparison to the untreated cells. 
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Figure.4.29: The effect of the crude extract of A. ilicifolius and its fractions on the 
growth of HT-29 cell line. Cells were seeded in 96-well plate and treated with different 
concentrations of both A. ilicifolius crude extract and fractions (166µg/ml) for 48h. The 
inhibition of HT-29 growth was assessed by MTT assay. The results represent the mean 
of triplicate measurement.  
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Figure 4.30: Photomicrographs of HT29 and CCD841 cells showing the effects 
A.ilicifolius fractions treatment; (A) CCD841 cells without treatment; (B) cells treated 
with 166.66 µg/ml F3; (C) HT29 cells without treatment; (D) HT29 cells treated with 
166.66 µg/ml F3 10x. F3; Fraction number 3. 
 
 
 
 
 
A B 
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4.22.1 Identification of active constituents of the active fractions  
We applied UPLC-PDA and LC-MS using positive mode in order to know the chemical 
structural information and to identify the phenolic constituents and other active 
compounds of A. ilicifolius F3. Approximately four compounds was detected in A. 
ilicifolius from them were characterized on the basis of the UV spectra and MS 
fragmentation patterns in comparison with literature or by searching the dictionary of 
natural products on DVD, Version 20:2 (2011) (CRC Press, Taylor & Francis Group, 
London, UK). In addition only one active compound was detected in A. ilicifolius and 
three of them were not identified. Typical HPLC-TOF/MS peaks and UV diode array 
chromatograms of the A. ilicifolius F3 fractions are shown in (Figure 4.31, 4.32). Table 
4.22 showed the identification of all the peaks detected with their retention time, UV 
max, observed m/z and the m/z of fragment ions. The A. ilicifolius F3 compounds 
include Stigmasterol at m/z 409.173 
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Table 4.22: Identification of phenolic compounds in A. ilicifolius F3 by UPLC-DAD and LC-MS data using positive 
ionization mode 
Sample Rt time(min) 
m/z of fragment ions 
observed 
Suggested 
formula 
 
Observed 
m/z 
Tentative 
identificatio
n 
M.W. 
(g/mol) 
A. ilicifolius 
F3 
0.994 280, 350, 191, 300, 254 C14H16N2O3 261.127 Unknown 260.12 
1.159 280, 350, 191, 300, 254 C19H20N6O 349.176 Unknown 348.17 
1.2761 280, 350, 191, 300, 254 C17H27O11 409.173 Stigmasterol 408.173 
1.475 280, 350, 191, 300, 254 C26H34N2O17 647.194 Unknown 646.19 
RT: Retention Time, M.W.: Molecular weight 
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Figure 4.31: HPLC-TOF/MS and UV diode array chromatograms of A. ilicifolius fraction 3 (F3); (A) Diode array detection 
UV spectra at 351 nm; (B) TOF MS peaks in positive mode ionization 
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Figure 4.32: Mass Spectrum (TOF MS ES+), chemical structure and UV max spectra of Stigmasterol (peak No. 4) 
identified A. ilicifolius F3 
Stigmasterol (M.W.: 412.69 g/mol
-1
) 
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5.1Discussion 
5.1.1 Antioxidant properties of the C. roseus and A. ilicifolius. 
Over the last two decades there has been an extreme interest in the role of oxygen-free 
radicals, usually known as reactive oxygen species (ROS), and of reactive nitrogen 
species (RNS) in experimental and clinical medicine (Halliwell & Gutteridge, 1999). In 
biological systems ROS/RNS are known to play a binary role in living systems, they 
can be either beneficial or harmful (Valko et al., 2004). Advantageous effects of ROS 
involve physiological roles in cellular responses to anoxia, as for instance in the 
function of a number of cellular signalling systems and in defence against infectious 
agents. In addition, at low concentrations ROS is the induction of a mitogenic response. 
In contrast, ROS at high concentrations can be an important broker of damage to cell 
structures, including membranes, lipids, nucleic acids and proteins (oxidative stress). 
The harmful effects of ROS are balanced by the antioxidant action of antioxidant 
enzymes in addition to non-enzymatic antioxidants. In spite of the presence of the cell’s 
antioxidant defence system to counteract oxidative damage from ROS, oxidative 
damage accumulates during the life cycle, and radical-related damage to DNA, to 
proteins and to lipids has been proposed to play a key role in the development of age-
dependent diseases such as arteriosclerosis, cancer, neurodegenerative, arthritis 
disorders and other situations (Valko et al., 2006).  
     This study evaluated the available evidence for the involvement of cellular oxidants 
in the incidence of colon cancer, in damage to cellular structures and in the role of 
signalling cascades by ROS. A discussion on the various protective pathways that may 
be provided by the antioxidant network against the deleterious action of free radicals, as 
well as the antioxidant interactions with various regulatory factors are also addressed. 
Medicinal plants have been presumed to be a rich resource of natural antioxidants that 
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counter balance’s these ROS, by removing the free radicals and minimizing the damage 
done too tissues.  
      The data of the present study showed that A. ilicifolious extract exhibited high 
antioxidant activity, as proven by FRAP results and its scavenging activity towards 
DPPH radicals. While extract of C. roseus were found to have possess antioxidant 
properties and a similar activity to that of BHT. Therefore the high antioxidant activity 
of A. ilicifolious, which led to more potent radical scavenging effects, is almost 
certainly associated with the high content of phenolic and flavonoids components. The 
total phenolic contents of A. ilicifolious and C. roseus are in accordance with the DPPH 
and FRAP results.  
     The phenolic compounds of antioxidant are important for helping the human body to 
destroy the free radicals that exist in our bodies. Many polyphenols, such as flavonoids, 
have been identified as powerful antioxidants. In addition they play a significant role in 
the treatment of many diseases. However, the antioxidant of the A. ilicifolius as 
observed in this study was not only from its phenolic contents, but could also be due to 
the presence of some other phytochemicals such as alkaloids and phenols. Different 
types of phenolic compounds have different antioxidant activities, which is dependent 
on their structure. The phenolics, especially flavonoids, were shown to protect 
mangroves (Agati et al., 2007). Moreover, the leaves of C. roseus are reported to have 
the extremely high levels of antioxidant properties (Rasool et al., 2011). 
5.1.2 In vivo Antioxidant properties and biochemical parameters 
     Anti-oxidant activity was found in experimental animal models; azoxymethane 
(AOM) increases oxidative injury to colon cells and it is believed that this process 
play’s a role in the etiology of colon cancer in rats (Al-Numair et al., 2011; Rodríguez‐
Ramiro et al., 2011). Our study showed that treatment of animals with C. roseus and A. 
ilicifolius extracts reduced the level of (MDA) and increases the activity of SOD. The 
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Catalase and SOD are responsible for the dissemination of free radicals, such as 
superoxide radicals.        
     During oxidative stress the body uses its defence mechanism to minimize the process 
of lipid peroxidation by using these antioxidant enzymes, thus, the activity of these 
enzymes become higher in early stages of AOM induction. However, when the insult 
continues for a long period of time, these enzymes become depleted and unable to fight 
against free radicals. Which means that in advanced stages of peroxidation due to AOM 
the activity of catalase and SOD, declined. While the activity of these enzymes continue 
to be high in treatment groups, the antioxidant properties of plant extracts against AOM 
induced free radicals. On the other hand, long term exposure to AOM led to significant 
increase of MDA level compared to the normal control group, indicating acute colon 
cell damage. Treatment of animals with C. roseus extracts and 5- Flourouracil 
significantly reduced the level of MDA and lipid peroxidation. There are numerous 
mechanisms of antioxidant substances having anticancer properties, such as by 
scavenging free radical (Jia et al., 2012). However, the treatment groups of both plants 
showed a significant increase in the activities of these antioxidant enzymes. Similarly, 
previous studies have established that by enhancing the activities of antioxidant 
enzymes (SOD and CAT) against the AOM-induced colon cancer in animals, that the 
reduction of oxidative stress may well play a role in the mechanism of its 
chemopreventive effects (Waly et al., 2012).  
     In the current study reduced lipid peroxidation was accompanied by a significant 
decrease in MDA level’s in groups treated with ethanol extracts from both plants. In 
addition, the extent of oxidative stress was demonstrated to directly correlate with the 
amount of total protein (T.P) and albumin (Alb) detectable in the blood which when 
induced by AOM inevitably leads to oxidative damage in erythrocytes. The increased 
secretion of T.P and Alb from the kidneys leads to an increase in the concentration of 
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urea in the bloodstream, moreover the Hb is then decreased in the blood due to anemia, 
but C. roseus treatment led to T.P, Alb, urea and LDH returning to normal levels. C. 
rosesus also led to a reduction of Hb, RBC, WBC and plt concentration.  
 Furthermore A.ilicifolius also directly correlates with the amount of T.P, Alb, 
urea and Hb detectable in the blood, along with restoring the level of T.P ,  Alb, urea and 
Hb to their normal values. The chemopreventive effects of these extracts may be due to 
the presence of the large amount of phenolic and flavonoids compounds and their 
antioxidant effects, as well as the free radical scavenging property of the plant. 
Likewise, the chemopreventive activity of the extract could be due to neutralization of 
the toxic compounds, produced by converting AOM to a highly toxic metabolite during 
WNT pathway. 
     The results of this current study are in agreement with the results published by 
Shahidi & Chandrasekara (2010), that states chemopreventive effects could be 
attributed to their ability to reduce free radical formation and to scavenge free radicals. 
Several reports have shown the relationship between carcinogenesis and oxidative 
stress. An inflammatory response is typically accompanied by a generation of free 
radicals, stimulation of cytokines, chemokines, growth and angiogenic factors. Free 
radicals, capable of both directly damaging DNA and affecting the DNA repair 
machinery, enhance genetic instability of affected cells, thus contributing to the first 
stage of neoplastic transformation, also known as initiation (Dobrovolskaia & Kozlov, 
2005).  
5.1.3 Acute oral toxicity tests of C. roseus and A. ilicifolius 
Many clinical and toxicological studies have been carried out for medicinal plant 
extracts to ensure the secure use and safeties of these plants. In Global Harmonized 
System of Classification and Labelling Of Chemical and Environmental Protection 
Agency: Health Effects Test Guidelines, the LD 50 value higher than 5000mg/Kg 
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showed by plants extracts are practically safe (Winder et al., 2005). Therefore, the 
investigated plants extracts are toxicologically safe by oral administration, since there 
were no significant differences observed when examining the C. roseus and A. 
ilicifolius treated groups in comparison to the control group regarding liver and kidney 
functions tests. Thus, our findings support the logical usage of these plants in Malaysian 
folk medicine. 
5.1.4 Colon cancer mechanism and chemopreventive activity of medicinal plants 
     Nutritional factors play an important role in human health as well as in the 
development of a number of chronic diseases, including cancer (Rogers et al., 1993). 
While genetics along with environmental issues are identified as contributors in the 
etiology of colonic carcinoma, nutritional factors also play a major role (Vogelstein et 
al., 1988). Plant resources, namely vegetables, fruits and spices have attracted extensive 
study because of their chemoprotective properties. Many are known to possess anti-
inflammatory, antioxidant and antitumour or cancer chemoprevention activities (Gupta 
et al., 2010). Aberrant crypt foci are generally considered as early markers of primary 
neoplastic change in the human large intestine, as seen in the experimental colon 
carcinogenesis AOM rat model (Park et al., 1997). Colon carcinogenesis is a multistage 
process, quick cell proliferation as well as ablation of apoptosis are initial incidences for 
its progression (Patel et al., 2009). The rodent AOM model of colon carcinogenesis 
represents a valuable approach for the development of strategies for chemoprevention. 
This model recapitulates many of the clinical, pathologic and molecular features 
occurring in sporadic human colorectal cancer (80% of cases), including crypt cell 
hyper proliferation and ACF formation that are considered as premalignant precursors 
(Bird & Good, 2000).  
     The preneoplastic lesions, such as ACF, which are detected 30-45 days after AOM 
administration, have been extensively used as an endpoint in short-term chemopre-
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ventive studies (Bird & Good, 2000; Pereira et al., 1994).  In fact, ACFs are considered 
to be the ‘gold standard’ of colon carcinogenesis biomarkers (Pretlow et al., 2004).  
             In the present study, both plants showed a reduction in the number of 
preneoplastic lesions (multicrypt aberrant and hyper proliferative crypts) at the surface 
of the colon. Importantly, our results showed that rats fed with C. roseus and A. 
ilicifolius inhibited the foci that containing multicrypt, as well as the total number of 
aberrant crypts. These plants considerably decreased AOM-induced total colonic ACF 
formation and multicrypt aberrant crypt growth. A majority of ACF exhibited 
morphological atypia. Using a grading system to enumerate atypia based on nuclear 
morphology (elongation and stratification), it became evident that some ACF exhibited 
a grade 4 nuclear atypia. Nuclear elongation and stratifications are the 2 main 
characteristics of dysplastic epithelium. Because dysplasia is generally considered to be 
a significant finding in the carcinogenic process, our observation that some ACF exhibit 
dysplasia presents strong evidence that ACF represent precursor lesions. Consistent 
with our results, Janakiram et al. (2008) showed that administration of dietary β-ionone 
significantly suppressed total colonic ACF formation when compared with AOM 
control group. In contrast to the results of the present study, pectin increased chemically 
induced colon cancer (Jacobs & Lupton, 1986). Soy concentrate does not protect against 
AOM-induced colon cancer (Bennink & Om, 1998). 
5.1.5 Immunohistochemistry 
Several research works involving human and animal models have shown that one of the 
earliest indications of preneoplasia is abnormal epithelial cell proliferation, maturation 
and differentiation. Increased cell proliferation has long been shown to play a crucial 
role in the initiation phase, as well as the promotion/progression stage of 
carcinogenesis. In this regard, PCNA is suggested as a factor in DNA replication by 
developing a moving foundation that could mediate the interaction of numerous proteins 
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with DNA, and hence, PCNA is reconsidered as an efficient biomarker for cell 
proliferation (Maga & Hübscher, 2003).  
     In the present study, C. roseus  and A. ilicifolius at all dosage levels significantly 
reduced the increase in proliferative index caused by AOM treatment in rats fed with the 
control diet, suggesting that C. roseus and A. ilicifolius, through their ability to restrain 
oxidative stress could also inhibit the consequent activation of the signalling pathways 
involved in the proliferation and thereby the progression of preneoplastic lesions in the 
colonic epithelial cells. 
5.1.6 Gene expression 
     Progressive inhibition of apoptosis has been described as taking place during the 
transformation of colorectal epithelium to carcinoma (Anti et al., 2001). Expression of 
the p53 gene and those of the bcl-2 family (the best known of the genes involved in the 
regulation of epithelial cell apoptosis) also change progressively as the tissue passes 
through the consecutive stages of normal mucosa, adenoma and carcinoma 
(Bousserouel et al., 2010b). A good number of antitumour agents obtained from plants 
exercise their effect through apoptosis induction in cancer cells (Kundu et al., 2005). 
Cell proliferation and apoptosis biomarkers are generally utilized to examine the 
efficacy of potential chemopreventive agents (Kohno et al., 2006).  
     The carcinogenic process entails alterations in the balance between cell death and 
cell renewal that regulate the normal cellular homeostasis in the colonic mucosa. The 
tumour suppressor protein p53 is known to play an important role in apoptosis and cell 
cycle arrest (Deuk Kim et al., 2006). Bcl-2 protein expression in colorectal tumours  
(Furihata et al., 1999). Bcl-2 was the first gene to be implicated in the regulation 
(inhibition) of apoptosis. Accumulating data shows that p53 protein is also associated in 
the apoptosis pathway acting in opposition to bcl-2, these studies have shown that p53 
can down-regulate bcl-2 gene expression (Miyashita et al., 1994). However, conflicting 
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reports have shown that p53 can up-regulate bcl-2 gene expression (Bousserouel et al., 
2011). Moreover, Bax was identified as a p53 early-response gene (Selvakumaran et al., 
1994), and a unique p53-regulated gene which induced apoptosis (Zhan et al., 1994), 
and affects Bcl-2 as an apoptosis antagonist (Oltval et al., 1993; Reed, 1994).  
     Indeed, this study showed that the AOM-triggered crypt cell hyper proliferation in 
the colonic mucosa was associated with the upsurge and development of preneoplastic 
lesions (ACF), but also with an elevated Bcl-2/Bax ratio (ratio >1). Our data showed 
that C. roseus and A. ilicifolius treatment induced the up-regulation of p53 gene 
expression, bcl-2 and pro-apoptotic Bax protein and the (Bcl-2/Bax ratio <1).  
 C. roseus triggered apoptosis may be at least in part responsible for its overall 
efficacy in inhibiting AOM-induced ACF formation in rat colons. These effects were 
associated with C. roseus and A. ilicifolius as they induced changes in the expression of 
apoptosis-related genes such as the subsequent Bcl-2/Bax ratio (anti-apoptotic versus 
pro-apoptotic gene and protein levels), which can be used as an indicator of 
chemopreventive efficacy, as previously reported for other drugs (Bousserouel et al., 
2010a; Bousserouel et al., 2011) and as shown here for C. roseus and A. ilicifolius.  
5.1.7 Phytochemicals investigation of the active fractions 
     By isolating and identifying extracts of C. roseus and A. ilicifolius this study has 
shown the presence of bioactive compounds in C. roseus, vindolin, ajmalicin, 
vindolidine, whilst stigmasterol was found in A. ilicifolius. As part of our investigation 
we have isolated and identified many alkaloid compounds including vindolin, ajmalicin 
and vindolidine in C. roseus (Tikhomiroff & Jolicoeur, 2002). On the other hand, a 
number of studies have identified many steroids compounds in the A. ilicifolius plant 
including stigmasterol (Wöstmann & Liebezeit, 2008b). The leaves are reported to have 
the highest antioxidant properties, amongst which the alkaloids fraction is the most 
active principle among the phytochemicals studied (Rasool et al., 2011). Phytosterols 
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are considered to be an anti-carcinogenic (Jones & Raeini‐Sarjaz, 2001). In agreement 
with our study, Tanaka (1997) found that the hesperdin phytochemical found in orange 
juice might inhibit the “initiation phase” of colon carcinogenesis, which led him to 
suggest that drinking orange juice would inhibit the “initiation stage” of colon 
carcinogenesis.  
5.2 Conclusion 
In conclusion, this study has shown that: 
1. C. roseus and A .ilicifolius ethanol extracts had relevant amount of phenolic, and 
flavonoid content and exhibited potent antioxidant activity in vitro by virtue of 
DPPH radical scavenging activities and ferric ion reducing power (FRAP). 
2. These ethanol extracts were toxicologically safe in vivo by oral administration. 
3. Our results indicated that C. roseus and A. ilicifolius exhibited potent chemo-
preventive effects that were proven by macroscopical, biochemical, 
hematological, histopathological, cell line and gene expression work. 
Accordingly, the plant extracts could be an effective herbal remedy against 
AOM-induced colon cancer. 
4. The mechanism underlining the chemoprotective effects of C. roseus and A. 
ilicifolius were suggested to be maintaining the endogenous antioxidant system 
of the colon and monitoring the expression of Bax, Bcl-2 and p53 genes. 
5. The antioxidant and chemoprotective activities of colon cancer were probably 
due to the isolated chemical compounds vindoline, vindolidine and ajmalicine 
from C. roseus and stegmasteroid from A. ilicifolius. 
6. High dose 500mg/kg extracts of C. roseus and A. ilicifolius exhibited 
chemoprotective activities, but less than the lower dose of 250mg/kg this 
activity may be attributed to the pro-oxidant of these plants. 
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7. From this study, promising potentials appear for the development of new 
therapy, which must focus on gene expression for the treatment of colon cancer. 
5.3 Future work 
1. Purification, identification and structure elucidation using 1D-and 2D-NMR 
spectroscopic processes fractions should be done for the unidentified chemical 
components. 
2. The fractionations of the plants extracts should be repeated several times to 
further isolate sufficient quantities of the active fractions in order to test their 
bioactivities on animals. 
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APPENNDIX A: Analytical Techniques and Preparations 
A1 Ferric reducing antioxidant power (FRAP) assay 
 
Figure A1. FRAP standard curve 
A2. DPPH Free radical scavenging assay 
 
Figure A2. DPPH standard curve 
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A3. Total Phenolic Content (TPC) 
 
Figure A3. Total Phenolic Content (TPC) standard curve 
A4. Total flavonoid Content (TFC) 
 
Figure A4. Flavonoid standard curve 
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A5. Superoxide Dismutase (SOD) assay 
 
Figure A5: SOD standard curve (µM) 
A6. Catalase (CAT) assay 
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Figure A6: Formaldehyde standard curve (µM) 
A7. TBARS assay 
 
Figure A7: MDA standard curve 
 
A8. Histopathology Techniques 
1- Routine slide preparation 
a- Tissue trimming and fixation 
The tissue processing started with trimming and excising the tissues in to small pieces 
of about 1 cm in size and then put in cassettes containing fresh 1-% buffered formalin of 
10:1 ratio of fixative to tissue for 48 hr. The purpose of fixation is to preserve tissues 
permanently in life-like sate as possible after removal of the tissues. 
b- Processing 
The technique of getting fixed tissue in to paraffin is called tissue processing. This 
process have been done by using automatic tissue processor. The main steps in this 
process were dehydration, clearing and infiltration in a programmed sequence. 
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c- Embedding 
After the above processes, the tissues were manually transferred from the cassettes and 
put in ti the blocks with molten paraffin over them, with proper orientation of tissue in 
the block of paraffin. 
d- Sectioning 
Once the melted paraffin was cooled and hardened the blocks were trimmed into an 
appropriately sized block and put into freezer under -4ºC for 1 hr before sectioning. 
Each block was than mounted in a specially designed slicing machine, a microtome. 
They were cut with steel knife into sections of 5 µm thickness. These sections were 
floated in a 40ºC warm water bath to avoid wrinkling, then they were picked up on a 
labeled glass microscopic slides. All these slides were then dried less than 50ºC 
temperature  
e- Staining 
Before staining, all the slides were deparaffinized by running them through xylenes I, II 
for 5 min each, in order to remove the paraffin wax out of the tissues and allow water 
soluble dyes to penetrate the section. The stains which were used in our experiment 
were H and E stains. Thick paraffin sections (5µm) of colon were de-waxed in xylene, 
dehydrated in series of alcohol to water then immersed in hematoxylin for 15 min. 
Sections were then differentiated with 1% acid alcohol and washed in tap water, 
followed by staining with eosin or 5 min. 
f- Mounting 
Finaly, to protect the stained sections from damage, the stained sections were 
dehydrated in series of alcohol, cleared in xylene and mounted with mounting media 
DPX and the use of coverslip in 45º angle then bubbles were removed carefully and left 
to dry overnight at room temperature. 
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2- Haematoxylin and Eosin (H&E) stain 
Reagents required  
1- Harris haematoxylin working solution 
2-Eosin working solution 
3-0.5% acid alcohol 
4-2% sodium acetate 
5-80% alcohol 
6-95% alcohol 
7-Absolute alcohol 
Procedure: 
1- Bring section to water 
2- Stain in Harris haematoxylin                  10  min 
3- Wash in running water until excess blue color gose off 
4- Differentiation: Dip 2 to 3X in 0.5% acid alcohol and wash in running tab water  
5- wash well in running tab water                2-3 min 
6- Blue section with 2% sodium acetate    2 sec 
7-Wash again in running tab water              2-3 min 
8- Rinse in 80% alcohol 
9- Stain in eosin solution                              5 min 
10- Dehydration: 95% alcohol I                   5 sec 
                            95% alcohol II                  2 min 
                            Absolute alcohol I             2 min 
                           Absolute alcohol II             2 min 
11- Clear in xylene                                        2 min x3 
12- Mount with DPX 
13- Wipe slide to remove excess xyline 
14- Label slide appropriately 
Results: 
Nuclei     blue 
Cytoplasm various shades of pink and red 
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A9. Standard Curve and efficiency for target and endogenous reference genes 
 
 
Figure Tbp standard curve 
 
Figure actba standard curve 
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Figure Hprt1 standard curve 
 
Figure p53 standard curve 
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Figure bax standard curve 
 
Figure Bcl2 standard curve 
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APENDIX B: Manufacturer kits instruction and procedures 
1. Catalase assay kit (Item No. 707002 Cayman) 
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2. Superoxide dismutase assay kit (Item No. 706002 Cayman) 
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3. TBARS (MDA) assay kit (Item No. 10009055 Cayman) 
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APPENDIX C: PhD Project selected photographs  
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Figure B1: Animal house experiment 
 
     
 
 
Figure B2: Column Chromatography and Thin layer Chromatography plate 
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Figure B3: Histopathology slide preparation 
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